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To my family… 
 
 
A few words about the title: 
 
The end of the rainbow…Some might think that it is impossible to find the end of the 
rainbow, some may say that it is a physical phenomenon and play of the light…However, 
there are stories and legends talking about a treasure at the end of the rainbow…Except from 
the treasure the most important is to try and go together with the colors of it…try and become 
a part of it and always try to ask yourself if it is worth believing in it or no…I do believe that 
we always have to use the facts and our imagination in order to be able one day, together with 
the colors of the rainbow to reach the “treasure” at the end of it… In our case and when it 
comes to medical science, the end of the rainbow will always be for the benefit of the 
patients…
  
ABSTRACT 
Aim. The aim of this thesis was to hunt for additional prognostic biomarkers in HPV positive 
TSCC and BOTSCC to identify patients that could if they wished, be enrolled in clinical 
trials for de-escalation of treatment.  
Background. Tonsillar squamous cell carcinoma (TSCC) and base of tongue squamous cell 
carcinoma (BOTSCC), which account for most oropharyngeal squamous cell carcinomas 
(OSCC) have been increasing in the last decades and now comprise almost half of all head 
and neck cancers (HNSCC) in Sweden. The main risk factors for HNSCC were originally 
considered to be smoking and alcohol however in 2007 the International Agency for 
Research on Cancer (IARC) acknowledged HPV infection as a risk factor for OSCC. It has 
been shown that patients with HPV positive OSCC and especially TSCC and BOTSCC have 
a much better clinical outcome (80% 3 year disease free survival, DFS) as compared to for 
patients with the corresponding HPV negative tumors (40%). Due the generally poor 
prognosis for HNSCC, treatment for HNSCC including TSCC and BOTSCC has been 
intensified, leading to more serious side effects for the patients. It has been proposed that due 
to the good prognosis of patients with HPV positive TSCC and BOTSCC such an aggressive 
treatment might be unnecessary and de-escalation of treatment would be of benefit. However, 
since 20% of patients with HPV positive tumors do not do well, additional prognostic 
biomarkers are needed for selecting patients that would be the best responders to less 
intensive treatment.  
Results. In paper I, high numbers of CD8+ tumor infiltrating lymphocytes (TILs) were shown 
to correlate with a favorable clinical outcome in both HPV DNA+ and HPV DNA- TSCC 
and BOTSCC. In addition, HPV DNA+ tumors were significantly more infiltrated than the 
HPV DNA- ones. In paper II, absence of HLA class I in HPV DNA+ OSCC was shown to be 
associated with increased survival of the patients while the opposite was true for normal 
expression. In paper III, the HLA-A*02 allele, common in the Scandinavian population, was 
demonstrated to be a negative prognostic factor for patients with HPV DNA+ TSCC and 
BOTSCC. Following that study, in papers IV and V, the expression of components of the 
antigen processing machinery (APM) were examined for nuclear and cytoplasmic staining 
and the absence of LMP10 nuclear staining as well as low LMP7 expression were disclosed 
to be correlated with increased survival of patients with HPV DNA+ TSCC and BOTSCC. 
Finally, in paper VI, biomarkers CD8+ TILs, HLA class I, HLA-A*02 and LMP10 were 
combined with clinical characteristics of age, stage of the patients with HPV DNA+ TSCC 
and BOTSCC in order to develop an algorithm allowing for prediction of the outcome of the 
patients and CD8+ TILs, age and stage of the patients were found to be most significant 
prognostic contributors.  
Conclusion. Investigating and combining our best prognostic biomarkers, we have developed 
an algorithm which makes use of different biomarker and clinical characteristics allowing for 
prediction of patients with good clinical outcome that will enable de-escalation of treatment.  
  
 
ΠΕΡΙΛΗΨΗ 
Σκοπός: Η εξεύρεση επιπρόσθετων προγνωστικών βιοδεικτών, σε ογκούς των αμυγδαλών και της βάσεως της γλώσσας σχετιζόμενους με 
την ύπαρξη του ιού των ανθρωπίνων κονδυλωμάτων (HPV). Η εξεύρεση αυτή των επιπρόσθετων βιοδεικτών μπορεί να οδηγήσει στην 
εξαγωγή πιο ασφαλών συμπερασμάτων σχετικά με την πρόγνωση της κλινική τους εικόνας. Η ασφαλέστερη αυτή πρόγνωση, θα μπορούσε 
να χρησιμοποιηθεί για την επιλογή ασθενών που θα μπορούσαν να συμμετάσχουν σε κλινικές δοκιμές, αυτοβούλως, με μοναδικό σκόπο την 
χρησιμοποίηση μιας πιο ήπιας και με λιγότερες επιπλοκές θεραπείας. 
Τι είναι γνωστό μέχρι τώρα: Η συχνότητα εμφανίσεως του καρκίνου των αμυγδαλών και της βάσεως της γλώσσας, που αποτελούν την 
πλειοψηφία των καρκίνων που διαγνώσκονται στην περιοχή του οροφάρυγγα, έχει αυξηθεί τις τελευταίες δεκαετίες, και σήμερα 
καταλαμβάνει περίπου το 50% των καρκίνων  στην περιοχή του κεφαλιού και του λαιμού, στην Σουηδία. Οι κυριότεροι παράγοντες 
σχετιζόμενοι με την συγκεκριμμένη  μορφή καρκίνου θεωρούνταν και είναι το κάπνισμα και η κατανάλωση αλκοόλ. Εντούτοις, το 2007 η 
Διεθνής Αντιπροσωπεία για την έρευνα στον καρκίνο (IARC) αναγνώρισε την μόλυνση με τον ιό των ανθρωπίνων κονδυλωμάτων ώς έναν 
επιπλέον καθοριστικό παράγοντα για την ανάπτυξη του συγκεκριμένου τύπου καρκίνου. Έχει αποδειχθεί από επιστημονικές μελέτες – με 
έναν από τους πρωτοπόρους στο πεδίο την κ. Δαλιάνη – ότι ασθενείς με καρκίνο των αμυγδαλών ή της βάσεως της γλώσσας που σχετίζοντε 
με την ύπαρξή του ιού, παρουσιάζουν πόλυ καλύτερη κλινική εικόνα κατόπιν θεραπείας, όταν συγκριθούν με αντίστοιχους ασθενείς των 
οποίων ο όγκος δεν σχετίζεται με την ύπαρξη του ιού (80% έναντι 40% ποσοστό επιβίωσης το λιγότερο 3 χρόνια μετά την διάγνωση). 
Εξαιτίας του γεγονότος ότι όγκοι που διαγνώσκονται στην περιοχή του κεφαλιού και του λαιμού σχετίζονται με σχετικά χαμηλά ποσοστά 
επιβίωσης των ασθενών αυτών (40%) η χορηγούμενη θεραπευτική αγωγή είναι εξαιρετικά αυξημένης έντασης. Όπως μπορεί εύκολα να γίνει 
κατανοητό, η αυξημένης αυτής έντασης θεραπεία, που κατα κύριο λόγο περιλαμβάνει ακτινοθεραπεία και χημειοθεραπεία, οδηγεί σε 
μεγαλύτερης εντάσεως βραχυπρόθεσμες και μακροπρόθεσμες παρενέργειες (ξηροστομία, αδυναμία κατάπωσης, προβλήματα ομιλίας). 
Εντούτοις, όπως προαναφέρθηκε, ασθενείς με όγκους θετικούς στον ιό HPV, παρουσιάζουν πολύ καλύτερη κλινική εικόνα και υπάρχει μια 
τάση στην επιστημονική κοινότητα σχετικά με την μείωση της έντασης της χορηγούμενης θεραπείας, που θα μπορούσε να οδηγήσει σε 
μείωση των προαναφερθέντων αρνητικών συνεπειών. Εξαιτίας του γεγονότος όμως ότι ένα 20% των ασθενών με θετικούς στον ιό όγκους 
δεν παρουσιάζει καλή κλινική εικόνα, επιπρόσθετοι βιοδείκτες είναι αναγκαίοι για την επιλογή ασθενών σε μελλοντικές δοκιμές για μείωση 
της έντασης της θεραπείας. 
Αποτελέσματα: Στην πρώτη μελέτη, επικεντρωθήκαμε στην μελέτη του αριθμού των κυτταροτοξικών Τ λεμφοκυττάρων. Δείξαμε ότι 
υψηλός αριθμός των λεμφοκυττάρων αυτών όταν έχουν διεισδύσει στην μάζα του καρκινικού όγκου σχετίζονται με καλή κλινική εικόνα των 
ασθενών με όγκους θετικούς στον ιό αλλά και στους μή θετικούς όγκους. Επιπροσθέτως, οι θετικοί στον ιό όγκοι βρέθηκαν να σχετίζονται με 
υψηλότερους αριθμούς Τ λεμφοκυττάρων στο εσωτερικό των όγκων. Στην δεύτερη κατα σειρά μελέτη μας επικεντρωθήκαμε στην μελέτη 
της έκφρασης του μείζονος συστήματος ιστοσυμβατότητας (HLA), το οποίο σχετίζεται με την παρουσίαση ενδοκυττάριων αντιγόνων στο 
εξωτερικό της κυτταρικής μεμβράνης των κυττάρων. Καταφέραμε να δείξουμε ότι απουσία του συστήματος αυτού από την επιφάνεια των 
κυττάρων σχετίζεται με εξαιρετικά μεγάλο ποσοστό επιβίωσης των ασθενών με όγκους θετικούς στον ιό, ενώ αντίθετη εικόνα παρουσιάζεται 
για ασθενείς με μη θετικούς όγκους. Στην τρίτη μελέτη ασχοληθήκαμε με το ευρέως διαδεδομένο στην Σκακδιναβία αλληλόμορφο HLA-
A*02, του μείζονος συστήματος ιστοσυμβατότητας. Η ύπαρξη του αλληλομόρφου αυτού σχετίζεται με μειωμένα ποσοστά επιβίωσης των 
ασθενών με θετικούς στον ιό όγκους. Στην τέταρτη και πέμπτη μελέτη μας επικεντρωθήκαμε στην μελέτη της έκφρασης πρωτεϊνικών 
υπομονάδων του πρώτεασώματος και του ενδοκυτταρικού μονοπατιού υπεύθυνου για την επεξεργασία και την παρουσίαση των 
ενδοκυττάρικών αντιγόνων από το σύμπλεγμα που προαναφέραμε. Στις δύο αυτές μελέτες δείξαμε ότι απουσία έκφρασης, όπως εντοπίζεται 
με την χρήση ανοσοϊστοχημείας, των πρωτεοσωμικών υπομονάδων LMP10 και LMP7, σχετίζεται με αυξημένα ποσοστά επιβίωσης ασθενών 
με θετικούς στον ιό όγκους. Τελικά, στην έκτη μελέτη μας όλοι οι προαναφερθέντες βιοδείκτες, των προηγούμενων μελετών, συνδιάστηκαν 
με κλινικά χαρακτηριστικά των ασθενών όπως η ηλικία, το στάδιο του καρκίνου και η διάγνωση με στόχο την δημιουργία ενός αλγορίθμου 
ικανού να παρέχει στοιχεία σχετικά με την πρόγνωση των ασθενών βασιζόμενο σε όλα τα προαναφερθέντα χαρακτηριστικά. Η ηλικία, ο 
υψηλός αριθμός των λεμφοκυττάρων στο εσωτερικό των όγκων καθώς επίσης και το στάδιο του καρκίνου βρέθηκαν να είναι οι πιο ισχυροί 
παράγοντες ικανοί να παρέχουν πληροφορίες σχετικά με την επιβίωση και την κλινική εικόνα των ασθενών.  
Επίλογος: Βασιζόμενοι στα στοιχεία και τα ευρήματα των μελετών μας όσον αφορά του προγνωστικούς βιοδείκτες και στην ταυτόχρονη 
χρήση κλινικών χαρακτηριστικών των ασθενών με θετικούς στον ιό όγκους, καταφέραμε να δημιουργήσουμε έναν αλγόριθμο ικανό να 
παρέχει στοιχεία σχετικά με την πρόγνωση των ασθενών αυτών, οι οποίοι θα μπορούσαν αργότερα να συμμετάσχουn σε κλινικές δοκιμές για 
εφαρμογή μικρότερης έντασης θεραπείας. Φυσικά επιπρόσθετες μελέτες χρειάζονται προκειμένου να αποδειχθεί η ορθότητα το αλγορίθμου 
και επιπλέον βιοδείκτες θα μπορούσαν να καταστήσουν τον αλγόριθμο αυτό περισσότερο ικανό για ασφαλέστερες προβλέψεις. Η 
προσπάθεια συνεχίζεται...    
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1 INTRODUCTION 
The human body has been designed to keep invaders away and to protect itself from 
exogenous and endogenous enemies. There are different ways of doing this, comprising of 
natural and physical barriers, such as skin and mucosa as well as internally built in or 
acquired mechanisms such as innate and adaptive immunity. 
One of the “internal” enemies that has been recognized since old times is cancer.  Cancer 
was recognized as a disease several thousand years ago
 
and a lot of different theories 
regarding the etiology of the disease have been described over the years
1
.   
 
Among other theories, infectious agents were linked with cancer development and as early 
as 1907, an Italian physician named Giusseppe Ciuffo described the viral etiology of 
human warts. Nevertheless, this finding was not appreciated by the scientific community 
and it took several decades before scientists realized that infectious agents (viruses)  were 
linked to human malignancies. Before that, already in 1908, two Danish scientists, 
Vilhelm Ellerman and Olaf Bang showed that a cell-free filtrate of chicken leukemia cells 
was able to induce the disease in healthy chicken
2
.  
 
The big revolution within the field of tumour virology was in 1911, when Peyton Rous 
showed that the inoculation of cell-free extracts from sarcomas of diseased chickens into 
healthy chickens led to tumour development, describing for the first time transmission of a 
tumor virus (Rous Sarcoma Virus, RSV)
3
. This led to a new paradigm in cancer research. 
Despite the fact that his research was not understood in the beginning, the recognition of 
the importance of his finding lead to the Nobel Prize award in 1966. After the initial 
detection and confirmation of the RSV as an agent capable of causing tumour 
development, the field of tumour virology was expanded and more tumour viruses were 
discovered between 1930s and 1960s. So, is cancer a deregulation of the homeostasis of 
the cell, performed by external factors? The question still remains to be answered in the 
future. 
For now let us begin our journey… 
As described previously, the physical barriers in our bodies consist of the skin and the 
mucosa, which covers the openings in our bodies (e.g. mouth, colon, vagina, cervix, 
penis). Under normal circumstances, these physical barriers cannot be overcome by 
invaders and we remain healthy and uninfected. However, sometimes micro-injuries and 
openings can occur which enables the invaders and exogenous factors to enter into our 
body and cells. Such mechanisms are e.g. used by viruses and in this case by human 
papillomavirus (HPV).  
This thesis will mainly focus on HPV and components involved in immune recognition 
and presentation and cells of the immune system, in that they may serve as prognostic 
biomarkers in patients with oropharyngeal cancer and mainly tonsillar and base of tongue 
cancer. 
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1.1 HUMAN PAPILLOMAVIRUS (HPV) 
1.1.1 HPV and cancer, a brief history 
Professor Harald zur Hausen was awarded the Nobel Prize in 2008 for the discovery that 
the causative factor for cervical carcinogenesis was HPV. However, it had been noted 
much earlier that prostitutes and married women had a higher frequency of cervical cancer 
than nuns and virgins in a study performed between 1760 and 1839 in Verona Italy. This 
higher incidence was assumed to be due to sexual contact and an unknown factor that was 
causing the cancer
4
. 
Studies were then initiated in order to identify the unknown factor and in the beginning the 
carcinogenesis mechanism was mainly attributed to herpes simplex virus 2 (HSV2) but 
studies failed to prove this assumption. During the 1970’s HSV2 was substituted by HPV 
and after many attempts finally, in 1982, the genome of HPV16 was sequenced from 
cervical cancer biopsies
5, 6
. In 1983, Southern blot from cervical cancer specimens by zur 
Hausen and his colleagues demonstrated DNA from HPV16. Following that the genome 
of HPV was isolated from other cancer types mainly from the anogenital region (e.g. 
vulva, vagina, penis and anus)
7
. Furthermore, already during this period there was a 
suspicion of an association between HPV and head and neck cancer
8, 9
. 
However, it was not before the early 2000s, that an association between HPV and 
oropharyngeal squamous cell carcinoma and especially tonsillar cancer and base of tongue 
cancer was disclosed
10-13
. These data were confirmed by our research group and also by 
others, and in 2007, the International Agency for Research on Cancer (IARC) 
acknowledged HPV infection as a risk factor for oropharyngeal squamous cell carcinoma 
(OSCC)
14
. 
 
1.1.2 Classification 
Human papillomaviruses (HPV) (>170 types have been identified so far) can be divided 
into two tropism groups: those that that have the ability to infect the keratinized epithelium 
leading to the development of the common warts; and those able to infect the mucosal 
epithelium lining of the most exposed cavities of the human body (mouth, throat, 
respiratory tract and genital and anogenital tracts). Cutaneous HPV infection is very 
common and highly prevalent worldwide and is mainly transmitted by skin-to-skin 
contact
14
.  
On the other hand mucosal HPV is generally transmitted by mucosa-to-mucosa contact 
and mainly by sexual intercourse. The risk of a HPV infection has been correlated with 
age, early sexual debut and increased number of sexual partners
15-20
. Mucosal types can 
also be divided into high risk (HR) and low risk (LR) types, depending on the ability to 
infect the mucosa and persist, leading to perturbation of the cellular homeostasis and the 
development of cancer
21
. 
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In addition to the division into two tropism groups, HPVs are also classified 
taxonomically, based on the sequence of one of their gene called L1 (see 1.1.3.2.1). The 
L1 gene helps in the classification of HPVs and phylogenetic trees can be constructed 
based on this
22, 23
. Viruses that share the same structure and organization characteristics 
belong to the same family, the “Papillomaviridae” family. HPVs are divided into genera, 
which are named after the Greek letters (alpha, beta, gamma, nu and mu). Each of the 
genera described above present branches indicated as “species” and then these “species” 
are divided into “types” (Figure 1). The types within each species present a genomic 
diversity in the L1 sequence of >=10%
21, 23
.  
 
Figure 1: Classification of human papillomaviruses in the different genera and species (adapted from Villiers 
et al. 2004
24
. 
 
1.1.3 Characteristics and genome organization of HPV 
HPVs (>170 types, with both potentially oncogenic and non-oncogenic types) are small 
non-enveloped viruses with a closed, double stranded, circular DNA genome that is 
packed in an icosahedral capsid of approximately 50-60 nm in diameter
25, 26 
(Figure 2A).  
The genome of HPV is approximately 8000 bp in length and can be divided into two 
“coding” regions, the early (E) and late (L) regions, and in between them lies the non-
coding regulatory region (NCCR), alternatively called the upstream control region (UCR) 
or the long control region (LCR). Two poly-adenylation sites, (pAE and pAL) separate the 
three regions of the viral genome
15, 16
.  
The E region covers approximately 50% of the whole genome and contains the so-called 
early genes or early open reading frames (ORFs), encoding for proteins responsible for 
the viral life cycle, invasion and use of the cellular machinery allowing for viral 
production (see sections 1.1.3.1 to 1.1.3.2 for more details). The early regulatory proteins 
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are E1, E2, E4, E5, E6, and E7 and in HPV-31 there is also E8, while the L region that 
covers around 40% of the genome contains the genes that encode the major and minor 
viral capsid proteins L1, L2
26, 27
. In between the E and L regions mentioned above, lies 
the LCR with regulatory functions for the viral genome and an illustration of the structure 
of the HPV genome is given in Figure 2B. 
 
 
Figure 2: A) Illustration of a HPV viral capsid, which consists of capsomers built up by the structural 
proteins of HPV L1 and L2. The size of the capsid is approximately 50 to 60nm in diameter. B) HPV 
genome organization. 
 
1.1.3.1 Early proteins and functions 
1.1.3.1.1 E1 and E2 
E1 has been shown; to be expressed at low levels in an infected cell and its active form is 
usually considered to be present only upon interaction with the E2 protein. Taken together, 
E1 and E2 are the two most important proteins during the initial steps of infection. They 
have the ability to interact with the DNA at specific regions and form complexes that 
allow for binding of other cellular proteins important and necessary for replication
23, 28
. 
E2 has the capacity to bind viral DNA sequences that present a palindromic motif and as 
stated above recruit E1. There, E1 exhibits its helicase activity, thus making the chromatin 
accessible to the cellular replication machinery. The assembly of the aforementioned 
complex leads to the disassociation of E2, which then leads to the formation of a double 
hexameric ring formed by E1. This ring has the ability to mimic similar structures that are 
normally formed during replication in the host cell
28, 29
. In addition, there is evidence 
suggesting that E2 has the potential to lead to segregation of the viral DNA by creating a 
linkage between the replicating episomal molecules of the viral DNA and the mitotic 
chromosomes of the host
29
. 
A B 
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E2 seems to be a multifunctional protein of HPV. In a “dose dependent” manner E2 may 
exhibit both activating and suppressing properties. At low levels the expression of E2 acts 
as an activator of transcription which leads to the upregulation and overexpression of the 
viral oncogenes E6 and E7. In contrast, high E2 levels as seen at the initial phase of the 
infection keep the expression of the viral oncogenes E6 and E7 low. This characteristic of 
E2 is believed to be due to the fact that there are differences in the affinity presented by E2 
regarding different binding sites
27
. The tight control presented by E2 is of importance 
since deregulation of E2 can lead to uncontrolled overexpression of E6 and E7 thus 
leading to uncontrolled cell growth. 
The viral genome also has the ability to become a part of the host genome by integrating 
into it. Often, integration leads to the disruption of the E2 gene, which then leads to loss, 
or low levels of E2 and high expression of the E6 and E7 oncogenes as the suppressive 
ability of E2 is lost. However, this only explains a part of the story since it has been 
observed that integration it is not always crucial for the establishment of an active HPV 
infection and the development of cancer
25
. 
1.1.3.1.2 E4 
The E4 protein of HPV is expressed at the late phase of the viral infection and it is mainly 
involved in contacts with the cytoskeleton and has been implicated as a factor in the 
cytokeratin filament collapse in differentiating keratinocytes
30, 31
. Studies have shown that 
it is expressed simultaneously with the late region encoded L1 and L2 viral capsid proteins 
of HPV
32
. However, the role of the E4 protein is still enigmatic and some studies claim 
that E4 plays a role in viral replication transcription of the viral capsid proteins and in the 
release of the viral particles
30, 33, 34
. 
1.1.3.1.3 E5 
E5 protein is considered together with E6 and E7 as one of the transforming proteins of 
HPV though possibly with lower levels of transforming capacity as it has been shown both 
for human and bovine HPVs
35-38
. The transforming capacity of E5 implicates the EGFR as 
a key player of the effects caused by E5, especially for the potentially oncogenic high risk 
(HR) HPV16. In general, the E5 proteins of HPVs are hydrophobic proteins located in the 
membrane of intracellular compartments of the cell such as the endoplasmic reticulum 
(ER) and the Golgi apparatus (GA). A low or physiological expression level of E5 is 
correlated with its localization at the ER, while high E5 levels are associated with its 
presence at the Golgi apparatus and the nuclear envelope
39, 40
. The E5 of HPV 16 has been 
shown to be able to enhance growth factor signaling pathways. E5 is able to induce 
angiogenesis and anti-apoptosis by upregulating COX-2 expression. In addition, it has the 
potential to downregulate the tumor suppressors p21/p27 through the ET1 receptor
41
. 
Another important function of E5 and of particular interest for this thesis is its ability to 
downregulate the human leukocyte antigen (HLA) or major histocompatibility complex 
(MHC) of class I by accumulating the localization of the molecules in the Golgi apparatus. 
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The arrest of HLA class I in the Golgi apparatus is mainly due to two function of HPV E5. 
On the one hand, E5 as a membranous protein has the ability to lead to alkalization of the 
endomembrane compartment and on the other hand it has the ability to form direct 
interactions with the heavy chain of the HLA class I complex
42-45
. Through that, it 
prevents the HLA from translocating to the cellular surface and this may lead to the 
immune escape of the afforementioned cells, thus avoiding clearance by e.g. cytotoxic T 
lymphocytes. A schematic representation of the E5 mediated downregulation of HLA 
class I is given in Figure 3. Other studies also suggest that E5 has the potential to 
downregulate the HLA class II in keratinocytes that have been treated with interferon 
gamma (IFN-γ)42, 43, 46, 47. 
 
 
Figure 3: Illustration of the E5 mediated downregulation of HLA class I. As a highly hydrophobic protein, 
E5 of HPV is usually found in the membrane of interacellular compartments such as the ER and the GA. E5 
when accumulating in the GA induces alkalinisation of the endomembrane compartment which leads to the 
arrest of the HLA class I in the GA. In addition, direct interaction of E5 with the heavy chain of HLA class I 
complex has been shown. Additionally, when HPV genome is integrated it can lead to disruption of the HLA 
class I promoter leading in defective or no expression of HLA. 
1.1.3.1.4 E6 
The most important gene products of HPV with regard to transforming activity, are the 
two oncogenes E6 and E7. The E6 protein, is a well conserved protein of 151 amino acids. 
Its most known function is to bind to the tumor suppressor protein p53 and together with 
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the E6 associated protein (E6AP) leads to the ubiquitination and proteosomal degradation 
of it. This abrogates both cellular DNA repair and cell cycle control.  
 
E6 of HR HPVs exhibit other functions and also interacts also with many cellular 
components and proteins implicated in important signalling pathways. Briefly, E6 has the 
potential to interact with proteins that present a PDZ-domain and by that lead to the 
degradation of them. Moreover, E6 has been shown to be able to inhibit apoptosis by 
inhibiting molecules such as Bax and Bak. In addition, due to the afforementioned events 
E6 leads to cell cycle progression and cellular transformation
48, 49
. 
 
When it comes to differences between HR and non-oncogenic low-risk (LR) HPVs,  it has 
clearly been shown that the E6 protein of HR types has the potential to lead to p53 
degradation, while this is not the case for LR types. One possible explanation for this, 
which has not yet been fully elucidated, is the ability of the HR E6 to bind to two positions 
of  p53, thus making strong bonds that lead to the perturbation of the 3D structure of the 
protein. In contrast for LR types, binding is only seen in one position which is more easily 
broken
25, 50
. 
 
1.1.3.1.5 E7 
E7 is an oncogene encoded by the genome of HPV. It can bind the protein retinoblastoma 
(pRB) and destabilize its conformation. There are also interactions with other related 
tumor suppressor proteins, such as the p107 and p130. All the proteins of this family, have 
the ability to regulate and control the e2F family of transcription factors
51, 52
.Upon 
inactivation of pRB e.g. E2F is not inhibited and this leads to abrogation of the control of 
the cellular cycle (Figure 4). Upon, activation of the cell cycle, cyclin D inhibitors such as 
p16
Ink4a
 are activated in order to maintain homeostastis and inhibit uncontrolled cell 
growth and therefore, overexpression of p16
ink4a
 has previously been used as a surrogate 
marker for presence of HPV
53
. However, upregulation of p16
INK4a
 is not 100% associated 
with an HPV-positive status of the tumor and in about 10% of the cases there is a 
discrepancy between HPV and p16 positivity
54-57
.  
 
Of course the E7 protein of HPV exhibits more functions. It has the ability to inhibit the 
CDK-inhibitors p21 and p27 as the E5 does, which in turn leads to chromosomal 
instability. It has been also associated with interaction that lead to chromosomal alterations 
and modifications
58
. Another worth-considering function of E7 for this thesis is its ability 
to exhibit immune modulating functions. For example expression of E7 has been linked to 
downregulation of the major histocompatibility complex (MHC) which is the molecule 
responsible for antigen presentation of intracellular antigens
59, 60
. By downregulating 
HLA, HPV, as with many other viruses has the ability to evade the immune system and 
persist. Chronic infection and persistence is what leads to cellular alterations and 
combined with other factors may lead to the development of cancer.  
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1.1.3.2 Late proteins and functions 
1.1.3.2.1 L1 
L1 accounts for 80% of the viral capsid with 360 molecules, structured as capsomers. L1 
has the natural ability to assemble spontaneously, building virus-like particles (VLPs), 
which mimic the viral capsid, without L2 and DNA. This is an advantage that has been 
used in the development of VLP-vaccines against HPV, which serve as prophylactic 
vaccines against cervical cancer
61, 62
. 
1.1.3.2.2 L2 
L2 is the minor capsid protein and binds to L1 from the inside of the viral capsid, helping 
in the maturation and formation of the viral capsid as well as in the cellular uptake of the 
virions. A very nice review has been written by Wang et al.
63
 
 
1.1.4 Transmission and viral entry 
As described previously, mucosal HPVs have the ability to infect mucosal epithelium. The 
mechanism by which HPV gains access to the basal layer of the epithelium and enters the 
cells is not fully understood. There are studies showing that HPV transmission occurs via 
direct contact, however mucosa and skin without discontinuities are also suggested to be 
resistant to inoculation and infection by HPV
14, 64-66
. Thus, the main assumption is that 
HPVs gain access to the basal layers through micro traumas in the epithelium that makes 
the basal cells accessible to the virus. The mechanism of viral entry has not been 
elucidated yet, but there are studies showing that the virus is actually using heparin 
sulphate proteoglycans and a-6 integrins in order to enter and infect the aforementioned 
cells
67, 68
. Recently, syndecan-1 was also found to play an important role in the infection 
process
69
. Furthermore, Annexin A2 molecules able to form heterotetrameres have been 
associated with a mechanism supporting viral entry and currently small molecule 
inhibitors are being developed for blocking viral entry and infection
70
. 
1.1.5 Post entry events and characteristics of viral proteins 
If we accept sexual intercourse as the route of infection, a sexual intercourse in which one 
of the two partners already has an HPV infection, could lead to the establishment of a new 
infection in the other partner due to microablations of the epithelium either in the genital, 
anal or the oral tract. In this case, viral particles are released and can infect the basal layer 
of the epithelium. Usually, it is considered that the infection is followed by a genome 
amplification phase in which the virus is kept at a relatively low copy number
27, 71, 72
. This 
initial amplification of the viral genome, has been suggested to take place during the 
cellular S-phase and the viral genome copy number is maintained between 50 to 200 
copies/cell
73
. 
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After the internalization of the viral particle, a whole chain of events takes place and the 
life cycle of the virus begins, for further details see below.   
 
1.1.6 The viral life cycle and cellular transformation 
As soon as the virus gets access to the basal level of an epithelium a whole story of events 
starts taking place. After the internalization the genome of HPV remains episomal and 
following the S-phase of the host cell it starts replicating until it reaches a copy number of 
around 10 to 200 copies/cell
73
. 
During the early phase of infection, E1 and E2 early proteins levels are usually low. In 
addition, during the differentiation of the epithelia, the p97 promoter of the HPV genome 
facilitates the expression of the E6 and E7 genes, which are necessary for the entry in the 
S-phase of the cell cycle. During the epithelial differentiation the genome of HPV is also 
differentially expressed. As the cells from the basal layer differentiate and move into the 
higher epithelial layers, the p670 promoter of the HPV genome facilitates the expression 
of the viral replication proteins, as they have been described in the previous section (E1, 
E2, E4, E5). In these upper layers, there is an abundance of the aforementioned proteins, 
which leads to the amplification of the viral genome. When the keratinized epithelium 
starts to form, E4 is expressed more abundantly and accumulates in the cytoplasm of the 
cell, and it is also suggested to upregulate the production of the capsid proteins L1 and L2, 
which allow for viral assembly and release
27, 73
. The life cycle and the expression of the 
different viral proteins mentioned above is illustrated in Figure 4.  
 
 
 
 
 
 
 
 
 
Figure 4: Life cycle of HPV. In this figure the expression pattern of the proteins of HPV are given alongside 
their functions and the stage of the cycle as well as the part of the epithelium in which they are taking place. 
The above-described life cycle takes place whenever we face a HPV infection. Usually, 
the infections are not persistent and they regress, but in the absence of this regression, 
lesions may persist and may undergo malignant transformation. The mechanisms 
underlying this transformation have been described extensively and they are mainly based 
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on the functions of the oncogenes of HPV. E6 and E7, and to a lesser extent E5 have the 
ability to complement each other and alter the physiological properties leading to the 
immortalization of the human primary keratinocytes
74
. 
E6 and E7 have synergistic effects on transformation by acting on p53 and pRB 
respectively as described before. Inactivation of pRB by E7 has been shown to induce an 
increase in the levels of p53, which is then counteracted by the function of E6 that allows 
for p53 arrest and uncontrolled cell growth.  
Normally, during S-phase of the cell cycle, proteins called cyclins and the associated 
kinases (cyclin-dependent kinases) are induced upon specific mitotic signaling. Such a 
mitotic stimulation leads to the phosphorylation of pRB by the cyclin-CDK complexes, 
which in turn lead to the inhibition of the E2F binding. As mentioned above, when E7 
inhibits pRb, E2F transcription factors can activate and transcribe genes of the S-phase
27
. 
As also briefly mentioned above, one well-studied molecule associated with HR HPVs is 
the upregulation of p16
INK4a
 the natural inhibitor of the CDK4/ CDK6-CyclinD complex 
that promotes the S-phase
75
 (Figure 5). Notably, however in a recent study p16
INK4a 
up-
regulation in HPV positive cells has been shown to be due to the histone demethylase 
KDM6B, which is induced by HPV16 E7
52
. An illustration of the action of E6 and E7 is 
given in Figure 5. 
 
Figure 5: Mechanism of action of E6 and E7 in carcinogenesis. The main action of E6 and E7 as described is 
downregulation and degradation of p53 and pRB respectively, which allows for cellular transformation and 
immortalization and also inhibition of apoptosis, which in turn leads to the development of malignancies. p16 
is upregulated as a consequence of the uncontrolled gene transcription and cell cycle.  
 
  21 
1.1.7 HPV associated diseases and cancer types 
As stated, HPV has the natural ability to infect epithelia. It can cause benign warts, 
condylomas and cancer.  
Cellular proliferation and transformation is a result of persistent infections together with 
other factors. For example, in immune suppressed individuals benign warts as well as 
HPV induced tumors occur more frequently. Moreover, in the genetic disease 
epidermodysplasia verruciformis  (EV) research has shown that preordained deficiencies 
presented in the cutaneous immunity of patients with EV makes these patients more 
susceptible to infections in persistent infections with HPV
76
. These genetic defects, lead to 
an inability to clear infections. More specifically patients with EV usually have persistent 
HPV5, HPV8 and HPV14d infections, which are the most common types associated with 
malignant transformation of EV
77
. In addition, while most HPV 5, 8 and 14d infections are 
mainly asymptomatic, in some cases they cause verrucae and a minority of these cases 
may lead to the malignant transformation of the skin and also the anogenital tract
76
.  
However, best known among the associations of HPV and squamous cell cancer is the 
association of HPV with cervical cancer, where 90-99% of all cases are found to be 
positive for HPV
78-80
. Moreover, HPV is also found in other anogenital cancers, such as 
anal cancer (~ 80% of cases positive), vulvar cancer (~ 40% of cases positive), vaginal 
cancer (~ 80% of cases positive), and penile cancer (~ 40% of cases positive)
81-83
.  Finally, 
as mentioned above the association between HPV and oropharyngeal squamous cell 
carcinoma (OSCC) more specifically tonsillar and base of tongue cancer, which is the 
main focus of this work and will be presented in more detail later (Section 1.5.2). 
1.2 THE MAJOR HISTOCOMPATIBILITY COMPLEX  
1.2.1 The major histocompatibility complex (MHC) - a general introduction 
This thesis deals with components of the major histocompatibility complex (MHC), 
especially with that of MHC class I antigens, so before going further it renders a short 
introduction. MHC molecules emerged as a result of large-scale chromosomal 
duplications, which occurred early in the chordate evolution, according to Susumu Ohno
84-
86
. There is also further evidence that MHC-like genes existed prior to the origin of the 
vertebrates and they might be in existence even before the separation of protostomes and 
deuterostomes
87
.  
In 1974, there was a study that at that time resulted in the revolution of the field of 
immunology, by which Doherty and Zinkernagel managed to show a correlation between 
cytotoxic T-lymphocytes and MHC molecules
88, 89
. What they actually show is that T cells 
are activated by a double signal based on the ability of the immune cells to recognize and 
distinguish between self and non-self-antigens. Based on that, they were able to explain 
the specificity presented by the immune surveillance. In addition, they proposed that MHC 
molecules must be of a specific haplotype in order to be recognized by the cytotoxic T 
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lymphocytes and also that antigens must be presented on MHC molecules. A self-antigen 
presented on the context of MHC is simply spared by the T cells, while a non-self-antigen 
such as one coming from a virus infected cell will likely trigger an immune response. 
MHC molecules are divided into classical and non-classical and the classical ones are 
implicated in the presentation of molecules triggering the immune response while the non-
classical are tolerogenic leading to the inhibition of the immune response
90
. In this thesis 
we will only focused on the classical molecules MHC class I and II. 
To conclude, it can clearly be seen that MHC existed early during evolution and its 
function seems to be very crucial for organisms for censoring of their environment and the 
recognition of self and non-self. Below therefore there will be an introduction of the HLA 
class I and II antigens denoted as human leukocyte antigens (HLA) in human, followed by 
an introduction of the immune system.  
1.2.2 HLA class I and II - a general introduction 
1.2.2.1 HLA class I 
The HLA class I molecules consist of a polymorphic alpha-chain which is called the heavy 
chain (HC) and an additional subunit called b2-microglobulin. These two together forms 
the HLA class I molecule, which has a peptide-biding cleft on the top of the structure. 
HLA class I molecules are expressed in nearly all cells in the body. In their peptide cleft 
they mainly present peptides of 8 to 10 amino acids long that are mainly obtained as 
products from intracellular degraded proteins from the proteasomes. In the cells, there is 
constant degradation and replacement of proteins. The majority of the degradation is 
catalyzed by the cytosolic proteasome
91-93
.  
Proteasomes are ancient enzymes that can also be found in archaebacteria. Because the 
proteasome is so well conserved it has been said that the entire HLA class I restricted 
antigen pathway has been evolved in such a way to process antigens and peptides that the 
proteasome generates. Thus, HLA class I molecules have the ability not only to present 
peptides from degraded cellular proteins, but also of intracellular pathogens. However, 
they can also occasionally bind peptides when they are on the surface of the cell
94-96
. 
When it comes to humans, there are two forms of the proteasome, one that is called the 
constitutive proteasome, which is always present degrading ubiquitinated proteins into 
peptides, and the other form is the so-called immunoproteasome. The constitutive 
proteasome is present in all normal cells, while the immunoproteasome is normally present 
upon stimulation when subunits of the constitutive proteasome are replaced by others as 
will be presented in detail below
97, 98
. The two have many similarities, but they also differ 
when it comes to the subunit composition of the active sites.  
The proteolytic subunits of the constitutive proteasome which is a 2.5 megadalton 
complex are β1 (or PSMB6, Y and δ), β2 (PSMB7, Z and MC14), β3 (PSMB5, X, MB1 
and ε) and they are expressed in most cells of the human body99, 100. The constitutive 
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proteasomes can be found in all cells. Peptides arising from the constitutive proteasome 
are 3 to 22 residues and therefore whole peptides do not always fit into the groove of the 
HLA class I molecules, which usually has an optimal capacity to fit in 8-10 aa peptides. 
By having the constitutive proteasome, cells have the ability to degrade proteins from the 
cytosolic compartment and present them on the context of HLA class I. This way they 
have the ability to scan for self-peptides and monitor their internal environment
101
. How 
do cells know which protein should be degraded? One of the most common pathways used 
by cells to identify unwanted proteins is the ATP-dependent ubiquitination pathway - 
which will not be presented here - but which marks proteins to be processed and degraded 
in the proteasome
100, 102
. 
After stimulation of cells with pro-inflammatory cytokines such as interferon-gamma 
(IFN-γ) or tumor necrosis factor alpha (TNF-α), which are usually present after pathogen 
infection the three catalytic/proteolytic subunits of the 20S proteasome (constitutive) are 
replaced by homologous subunits called LMP2, LMP7 and LMP10. As it can be clearly 
understood from its name, immunoproteasomes are mainly responsible from processing 
and degrading foreign proteins rather than self-proteins allowing for initiation of immune 
defense upon presentation of the antigens on the surface. Interestingly, as it has been 
found, immunoproteasomes are constitutively found in cells of the lymphoid organs such 
as, thymus and lymph nodes
97
. These subunits present distinct peptidases sites and cleave 
proteins in a distinct manner from constitutive particles and generate more peptides 
capable of binding to HLA class I molecules, thereby serving an important role in antigen 
presentation
103-105
. In addition, the modification, taking place after the subunit replacement 
mainly affects specificity, and not in the efficiency of how the two kinds of proteasomes 
process proteins.  
After degradation of the peptides irrespective of which proteasome is presently 
functioning in the cell, they are transferred and translocated from the cytosol to the 
endoplasmic reticulum (ER), where peptide loading on HLA takes place. Two molecules 
called TAP1 and TAP2 facilitate the translocation to the ER. These two molecules for the 
heterodimer called TAP (transporter associated with peptides), which will allow for 
translocation and loading of the peptide on to the HLA class I molecules. Both TAP1 and 
TAP2 are very important for efficient formation of the peptide-HLA complex and it has 
been shown that in mice if one of these is disrupted there is reduced expression of HLA 
class I on the surface of the cells. Furthermore, it has been shown that viruses such as 
cytomegalovirus and herpes simplex viruses 1 and 2 have the potential to block TAP. This 
leads to a reduced loading of viral peptides on HLA class I and reduced presentation on 
the cellular surface allowing for evasion of clearance by the CD8+ TILs. 
In parallel, the formation of HLA molecules is taking place in the ER and the HLA class I 
heavy chain (HC) is translocated to the ER by Sec61. Subsequently, HLA class I 
molecules are through the action of the chaperones called Calnexin and BiP correctly 
folded and bound to the beta2 macroglobulin chain. Following that Calnexin is no longer 
  24 
needed and is dissociated from the complex. Subsequently, Calreticulin and Erp53, which 
are responsible for stabilizing the HLA class I molecules, replace it. Another molecule 
called Tapasin allows then for the association of the HLA molecule to TAP1 and TAP2 
allowing for the loading of the peptides and the formation of the peptide-loading complex. 
Thereafter, the loaded HLA class I molecules are translocated to the cell surface through 
the ER and the Golgi complex and any non-completed or incorrect loading leads to their 
degradation
106-109
. However, in some cases, it has been shown that the aforementioned 
trimeric complex can disassemble and HC and β2m may appear as free forms on the cell 
surface
110
. HLA class I molecules are finally translocated to the cell surface, where they, if 
carrying peptides of pathogens or of mutated or altered host genes, potentially are 
recognized by CD8+ T cells. A simplified illustration of the antigen processing pathway in 
the context of HLA class I is given in Figure 6. 
 
Figure 6: Antigen processing pathway in the context of HLA class I. Only some of the examined molecules 
in the context of this thesis are presented to give the reader an idea of how the pathway works. In this case we 
see the immunoproteasome degrading antigens but the same principles are used from the constitutive 
proteasome as well, as described above. 
1.2.2.2 HLA class II 
The HLA class II molecules consist of two polymorphic chains called alpha and beta and 
there is no β2-microglobulin subunit. This makes a slight difference with HLA class I, but 
the overall structure is very similar. They also present a binding cleft on the top of the 
structure responsible for binding digested peptides. These peptides are usually obtained 
from the extracellular compartment. They either bind extracellular peptides directly, or 
peptides derived from extracellular proteins digested by proteases in the endosomal and 
lysosomal compartments. The size of peptides binding to HLA class II molecules varies 
and has been suggested to be larger than the size of those binding to the HLA class I 
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molecules because the groove that is on the top of the molecule is open at the ends thus 
enabling the binding of longer peptides. The loading of HLA class II molecules with 
peptides takes place in specialized vesicles formed into the cytoplasm before their 
translocation to the cell surface
111-113
. HLA class II molecules are expressed mainly in 
cells of the immune system and also tissues of the immune system such as DCs, 
mononuclear phagocytes, B-lymphocytes, endothelial cells and thymic epithelium. 
Finally, for HLA class II the responsive immune cells are the CD4+ T cells. It has to be 
mentioned that in some cases, dendritic cells are capable of ingesting whole cells that are 
e.g. infected with viruses. In these instances, these cells can process the antigens from the 
engulfed cells and transport their antigens into the cytoplasm. From there they can be 
transported to the ER where they are loaded on HLA class I molecules that can be 
presented for recognition by CD8+ T cells
114
. This process is called cross-presentation. 
1.3 THE IMMUNE SYSTEM – A BRIEF INTRODUCTION 
Host immune defense consists of two parts: the innate immunity, which resembles the first 
line of defense against infections and the adaptive immunity which is slower but more 
specific and effective in combating infectious agents. The players of both systems develop 
in the bone marrow, but afterwards they show different migration patterns. 
1.3.1 Innate immunity 
The main characteristic of the innate immunity is its presence naturally in the human body 
prior to any encountering of pathogens. It has been mentioned previously that one of the 
first lines of defense is the skin, which forms tight junctions and does not allow entry of 
pathogens. Another form of innate immunity is the normal flora on our skin, which 
prevents pathogenic bacteria from being introduced and proliferating and probably causing 
infections and perturbation of homeostasis. Following down from the epithelium there are 
also other mechanisms such as secretion of mucus which with its colloidal texture does not 
allow pathogens to adhere and establish an infection and also here the complement system 
which leads to phagocytosis of pathogens can be included but it will not be presented in 
detail here
115, 116
.  
In the innate immunity there is also the “cellular compartment” which is mainly comprised 
of cells having the capability to phagocytize pathogens and also activate and recruit other 
immune cells. Granulocytes account for the vast majority of circulating leukocytes, and 
they can release antimicrobial peptides and enzymes that have the ability to combat 
invaders
117
. Dendritic cells (DC) are also cells of the innate immune system that have the 
ability to phagocytize pathogens and after enzymatic digestion and degradation to present 
peptides on their surface allowing for stimulation and activation of other cell types of the 
immune system. A big part of their function is the bridging between the innate and the 
adaptive immunity as will be presented below. In addition, they have the ability to lead to 
increased migration of cells at the areas of infection
118
. Macrophages, which also have 
phagocytic capabilities and mainly work on the clearance of cellular debris are another 
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category in this group, as are NK cells. The function of NK cells is mainly to eliminate 
cells that are found to be under stress and one of their very specific functions is to 
eliminate and clear cells that have lost their ability to express HLA molecules on their 
surface
119, 120
. Of course all of these different cells are not independent of each other and 
there is interplay, which is also facilitated by the secretion of different types of cytokines 
and chemokines
121
. In this thesis we mainly focused on cells of the adaptive immunity and 
thus this part will be presented in more detail below. 
1.3.2 Adaptive immunity  
Innate immunity, with all of the cells and mechanisms presented briefly above, has the 
ability to clear and eliminate most of the pathogens infecting the human body. However, 
in some cases pathogens manage to overcome this line of defense and after that a more 
specific response is needed in order for the pathogens to be eliminated and homeostasis of 
the human body to be maintained. This requires the important bridging between the innate 
and adaptive immune response. 
Of course there are many different molecules that can be recognized by the immune 
system and serve as antigens, but here our focus will be on protein antigens. Conventional 
DCs are constantly sampling and scanning the epithelial microenvironment for any foreign 
antigens. Whenever a DC encounters an antigen that is foreign it exhibits its main 
function, which is to phagocytize it. The recognition is facilitated by receptors that they 
express on their surface, allowing them to recognize microbial patterns. Upon 
phagocytosis DCs start losing adhesiveness for epithelia and start migrating to the lymph 
nodes through the lymphatic vessels. During this process they start to mature and change 
from phagocytic cells to antigen presenting cells (APC) which are capable of stimulating T 
cells.  
Here, I believe that a short and summarized description of a lymph node is relevant. 
Lymph nodes are organs of the lymphatic system that are widely distributed through the 
whole human body. Lymph nodes resemble the main sites in which the activation of 
adaptive immune responses takes place. In order for an immune response to be initiated, 
the antigen specific T and B cells have to come into contact with professional antigen 
presenting cells (APCs) and these are usually the peripheral and the follicular DCs
122
. 
Thus, the first line is usually interaction and internalization by DCs, which then present the 
peptides to naïve T cells in the lymph node, thus initiating an immune reaction for the 
elimination of the antigen or it may become tolerant or die to avoid causing autoimmunity. 
This decision is mainly facilitated by “information” offered in the lymph nodes123. In the 
lymph nodes, there are separate compartments where T and B cells located. B cells are 
found in the follicles (follicular B cells) or in the cortex, which are situated in the 
periphery of the lymph nodes, while T cells are mainly in the paracortex, which is usually 
called T cell region, adjacent to the cortex, but on the inner side of the lymph node and 
closer to the medulla of the node which is mainly rich in antibody-secreting plasma cells 
which are then close to the efferent lymphatic vessel. This separation is mainly facilitated 
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by chemokines and specific receptors which are expressed by B and T cells
124, 125
. An 
illustration of the lymph node and the different compartments is given in Figure 7. The 
lymph node is where B and T cells mainly interact after an antigen has been presented by 
DCs or after direct contact with their receptors, but prior to that some words about B and 
T-cell development will follow. 
 
Figure 7: Illustration of the structure and organization of a lymph node. The different compartments are 
given alongside the location of the immune cells within the structure. 
Both B and T cells develop in the bone marrow from hematopoietic precursor cells 
however, they follow different patterns when it comes to their development. Of course it is 
difficult for the whole development process to be described here and for that reason; the 
amazing papers describing the process can be read by someone really interested. For B 
cells, the development consists of many different stages where they undergo 
conformational changes and genetic rearrangements with regards to the expression of the 
heavy and light chains of the immunoglobulins presented on their surface (For review see 
Pieper et al.
126
). After these different steps, the so-called immature B cells undergo 
selection regarding their self-reactivity and their ability to survive in the peripheral 
lymphatic system. Immature B cells that bind self-antigens undergo further receptor 
rearrangements or die or are finally inactivated. All of the steps up to this stage are taking 
place in the bone marrow and once they finally reach the stage of the mature or naïve B 
cells, they acquire the ability to migrate in the periphery and come into contact with 
antigens
126
.  
T cells also originate and start their life span in the bone marrow, from common lymphoid 
progenitors with the B cells. After that some of these progenitors migrate to the thymus 
where they start proliferating. There cellular interactions with the thymic stroma allow for 
T cell development which also takes place in different steps. Here there are also receptor 
development and gene rearrangements -although quite different to that of B cells- which 
allow for the positive and negative selection of the T cells in order for them to be reactive 
against foreign antigens, but not self-antigens. Initially, T cells do not express any of the 
CD4 and CD8 receptors and that is why they are called double negative. Following this 
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the double negative cell can give rise to two lineages of T cells and the most common and 
larger is the so-called alpha-beta lineage, which is at this stage comprised of double 
positive cells. Most cells then die in the thymus as they undergo selection for interaction 
with self-antigens and self-HLA molecules and finally the outcome is T cells, which are 
single positive either for CD4 or for CD8 receptors. They are then called mature T cells 
and they are exported from the thymus, and migrate to the periphery and the peripheral 
lymphatic organs and tissues. Indeed this is a very short summary of the developmental 
steps of T cells and therefore it is highly recommended that one reads the very nice and 
informative reviews from Koch and Radtke
127
 and also from Juan Carlos Zúñiga-
Pflücker
128
.  
As mentioned, the bridging between the innate and adaptive immunity is facilitated by 
DCs, which are also called professional antigen presenting cells (APC). DCs can after 
phagocytizing pathogens or antibody or complement covered cells, degrade them in the 
lysosomes. The degraded antigens are then presented by DCs mainly in the context of 
HLA class II molecules to the residential CD4+ T helper cells, which then have the ability 
to initiate effector actions. Intracellular pathogens such as viruses on the other hand are 
mainly degraded in the cytoplasm and not in the lysosomes as described previously and 
then the peptides are presented onto HLA class I molecules. These complexes then have 
the ability to activate CD8+ cytotoxic T cells that can together with other signals eliminate 
the infected cells
129, 130
. 
1.3.3 HPV and interactions with the immune system 
HPV is an invader having the potential to infect cells in our body and initiate an infection 
with the only aim of reproducing itself. As an invader HPV should be recognized as a 
foreign body by our immune system and be cleared by various immune associated 
mechanisms, and a fine balance is usually the case, since HPV has evolved mechanisms to 
avoid immune recognition and clearance. However, in some cases, and especially upon 
immunosuppression or under special conditions, the balance between the presence of HPV 
and the immune system is disturbed and pathological conditions emerge.  
At the initial stages of the infection with HPV, the innate immune system is the one that 
should sense the presence of a non-self-factor. The first line of defense is the epidermis, 
which is a natural barrier against pathogens. Upon the presence of micro-wounds as has 
been already described, HPV gets access to and can infect the cells of the basal layer of the 
epithelium. Being the main target of HPV, keratinocytes play an important role. 
Keratinocytes can be considered as a part of the innate immune system, since they have 
been described as sentinels
131. It is shown that they can act as “non-professional” antigen 
presenting cells and have the ability to promote the expression of cytokines of the Th1 and 
Th2 types and they can also elicit in CD4+ and CD8+ memory T cells
132
.  
Furthermore, keratinocytes have Toll-like receptors (TLRs) both on their surface and in 
endosomes that can recognize the presence of pathogen associated molecular patterns 
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(PAMPs). There are many different types of TLRs that have been described namely TLR-
1, TLR-2 etc. that can sense different patterns from double stranded RNA (dsRNA) to 
double stranded CpG rich DNA. The activation of TLRs by PAMPs leads to signaling 
cascades related to innate and adaptive immune responses. In addition, activation of the 
aforementioned receptors leads to the production of cytokines that create a strong pro-
inflammatory environment and as an example TLR-9 in human keratinocytes leads to the 
production of type-1 IFN, TNF-α, CCL2, CCL20 and CXCL9133, 134. The main function of 
interferons (IFNs) is to mediate protection of the cells against viruses through three 
distinct pathways; antiviral; anti-proliferative and immunostimulatory mechanisms.  
Apart from the keratinocytes, at the primary sites of infection there are the professional 
antigen-presenting cells (APC), called dendritic cells (DC). In the epidermis DCs are 
mainly comprised of Langerhans cells and in the dermis from 3 other subsets of cells, 
which are not of importance for this thesis and thus will not be presented
135
. Immature 
DCs, have the natural ability to continuously sample the extracellular matrix and 
surroundings for pathogens and microbes that may have entered through pattern 
recognition receptors (PRR). Upon engulfment of a microbe or in our case viral products, 
they undergo a change called maturation and they migrate to the regional lymph nodes.  
The engulfed products or microbes are then digested into peptides, after which they are 
presented on the major histocompatibility complex (MHC) or in human, human leukocyte 
antigen (HLA). Through presentation of the peptides on HLA by DCs they are then able to 
bind to cytotoxic CD8+ T cells or CD4+ helper T cells and elicit different immune 
responses in the presence of different cytokine and chemokine environments. Upon 
activation, CD4+ T cells start to proliferate and they may end up in two different types 
called Th1 and Th2 depending on the cytokine environment again. IFN-γ favors the Th1 
response. In the situation of a viral infection a Th1 response is of importance since 
secretion of IFN-γ induces maturation of CD8+ T cells and also activates macrophages 
and natural killer (NK) cells
136
. 
1.3.3.1 HPV, antigen processing and HLA class I 
As has been shown for many viruses, HPV has, through evolution developed the natural 
ability to interact with various components within the intracellular and cytoplasmic 
compartment. In contrast to other viruses, which have the ability to interfere or interact 
with many of the APM components, HPV16 has only been shown to be able to interact 
with HLA class I
91
. Here in this thesis we have shown similar results. In addition, other 
reports have shown that HPV E5 proteins that are mainly found in the Golgi apparatus, 
have the ability to bind the heavy chain of HLA class I and thus retain it in the Golgi and 
hence not allowing for antigen presentation
42, 47, 137, 138
. Other studies have found that E7 
may have the ability to repress the HLA class I promoter leading to decreased presentation 
of HLA class I on the surface
139
.   
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1.3.3.2 HPV and antibody responses 
During natural HPV infection antibody titers are directed mainly against L1, and these can 
be seen as a sign of past infection. Notably, antibody titers obtained naturally are generally 
much lower than those obtained through vaccination (see 1.3.4).  
1.3.3.3 HPV and T-cell responses 
While antibodies are suggested to block viral infection, it has been suggested that the 
cellular immune system is of ultimate value for clearing an established infection. More 
specifically, T cell responses are of importance comprising both virus specific T cell 
responses (CD8+ CTLs) and also CD4+ T cells producing IL2 and IFN-γ producing Th1 
cells
140
. Studies have shown that in cervical cancer, the presence of T cells was not 
associated with the production of granzyme B, which is a mechanism utilized by T cells 
for inducing apoptosis of the infected cells. Instead it was found that PD-1 was expressed 
as a sign of T cell exhaustion resulting in ineffective elimination of the infected cells
141
. 
1.3.3.4 HPV and evasion of immune system 
HPV infections are usually cleared by the immune system, or at least they are controlled in 
most cases. This is demonstrated, in that most of us clear warts, and that in the majority of 
the cases, young women, who have developed an incident HPV infection will show 
clearance of this infection within 12 to 30 months
142
. In contrast, immunosuppressed 
patients present HPV associated lesions, e.g. warts and tumors much more frequently than 
then normal population and have more difficulties in clearing them.  
Cutaneous HPVs can to some extent evade the immune system in that the life cycle is 
limited to the differentiating keratinocytes
133
. In addition, the HPV life cycle does not 
present any blood borne phase and there is no lytic cycle and thus no viral particles are 
released, which could serve as danger signals for the immune system to be activated
143
. 
Furthermore, HPV is characterized by sub-optimal codon usage and this is something that 
keeps the viral proteins low, thus avoiding detection from the immune system. 
Other studies have suggested that APCs in the epidermis, the Langerhans cells (LC) even 
upon engulfment of HPV capsid are not able to elicit an immune response and that the 
cytokine profile in the microenvironment is also very crucial for the establishment of a 
Th1 or a Th2 response
144
. Most of the time this profile is more leading towards a Th2 
response, which as has been stated previously is not optimal for clearance of virally 
infected cells
145
. HPV has also been suggested to be able to inhibit type 1 interferons (IFN-
alpha and beta) through its oncogenes that interfere with components named interferon 
regulatory factors (IRFs) and are responsible for the interferon pathways
133
. Finally, it has 
been shown that HPV has the potential to upregulate the cellular deubiquitinase UCH1 in 
order to suppress the innate immune response elicited from keratinocytes
146
.  
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1.3.4 Vaccines and efficacy 
There are preventive vaccines against some HPV types and attempts have also been made 
to obtain therapeutic HPV vaccines
147, 148
, but so far the latter have not been as successful. 
The fact that the L1 protein of HPV has the natural ability to form viral particles without 
containing DNA, called virus like particles (VLPs) gave scientists the opportunity to 
develop vaccines against HPV.  
Based on that, today there are two vaccines available in the market which are prophylactic 
(Cervarix®, GlaxoSmithKline, UK and Gardasil®, Merck, USA) and more are on the 
way. In addition, there is an FDA approved 9-valent vaccine that has shown increased 
efficacy and no severe side effects (fever and pain at injection site).  
Gardasil is a quadrivalent vaccine covering the two most common HR HPV types  in 
cervical cancer in the Western world, HPV16 and 18, and it also covers two low-risk types 
(6 and 11) ) since they are associated with the development of common warts. Cervarix on 
the other hand covers only the two HR HPV types stated above. The efficacy of the 
vaccines is almost 100% with regard to prevention of HPV16 and HPV 18 infection in 
CINIII lesions after 4 years. There are also studies showing some cross protection against 
some other related HR HPV types
149-151
. In addition, more recent studies have suggested 
that the vaccines are indeed very effective and they have also shown that less than the 
three doses maybe sufficient. Protection is about 86% for HPV16 and 18 in CIN III lesions 
after 4 years following vaccination of women aged 15–25 years, with one dose, and two 
doses of the HPV-16/18 vaccine seems to protect against cervical HPV-16/18 infections, 
similar to the protection provided by the three-dose vaccination program
152
. The main 
mechanism being activated and responsible for the efficacy of vaccination is mainly 
attributed to the production of antibodies. It has been shown that Cervarix induces 
mainly Th1 responses while the opposite is true for Gardasil and despite the fact Th1 
responses are more preferable when it comes to viral infections, both vaccines have 
shown the same efficacy
153, 154
.  
In addition, there are studies in young adults showing that the oral prevalence of the 
HPV types covered by the vaccines mentioned above is much lower in vaccinated 
women as compared to the non-vaccinated ones, indicating the high efficacy of the 
vaccines. (Grün N, unpublished). Furthermore, in another study looking for oral HPV 
infections, they show that HPV prevalence 4 years after initiation of vaccination in Costa 
Rica, oral prevalence of HPV16 and 18 was much lower in the women that had been 
vaccinated compared to the control group, suggesting that the vaccine offers strong 
protection also against oral HPV infection. This also offers implications for prevention 
of the increasing HPV associated oropharyngeal cancer
155
. 
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1.4 HEAD AND NECK CANCER 
Head and neck cancer includes a wide range of different cancer types including tumors of 
the larynx, the hypopharynx the oropharynx, the epipharynx, the oral cavity, as well as the 
mobile tongue, the lip, the salivary glands, the sinuses, and the ear. Head and neck cancer 
represents the 6
th
 most common cancer worldwide and 90% of the cases are squamous cell 
carcinoma (SCC). Traditional risk factors for head neck squamous cell carcinoma 
(HNSCC) are smoking and alcohol, but also bethel chewing. The outcome for HNSCC is 
generally quite poor with <50% having a 5-year survival rate and this is not helped by the 
fact that the tumors are often detected late 
156
.  
In 1983, Syrjänen et al. suggested a possible association between HPV and oral squamous 
cell carcinoma
8, 9
.  The kick off from the Syrjänen group led the scientific community to 
initiate studies on the association between HPV and head and neck cancer, despite the fact 
that the community was very slow in its reaction and accumulated evidence supported the 
fact that HPV was mostly present in OSCC.  Thus, in 2007, the International Agency of 
Cancer Research (IARC) acknowledged HPV16 as a risk factor for oropharyngeal 
squamous cell carcinoma (OSCC), where tonsillar and base of tongue squamous cell 
cancer (TSCC and BOTSCC) dominate
157
. HPV is found in roughly 10-90% of all OSCC, 
and then mainly in TSCC and BOTSCC. Furthermore, HPV positive OSCC, especially 
HPV positive TSCC and BOTSCC, but not OSCC at other sites, have a much better 
clinical outcome than the corresponding HPV-negative tumors
158-161
.  
Less than 10% of other HNSCC are HPV positive and the role in the cancers of other sites 
has still to be investigated further, but there are reports suggesting that although HPV is 
rare, it may be a positive prognostic factor also in hypopharyngeal cancer
162
. 
Notably, the prevalence of OSCC has increased in the Western world in the last few 
decades and what is more intriguing is that prevalence of HPV-positive OSCC has also 
increased during the last decades, whilst on the other hand the prevalence of HPV-
negative cases has decreased. This has been shown for TSCC and BOTSCC since 1970 in 
Sweden 
163
. However, prevalence of HPV in OSCC varies depending on the characteristics 
of the study population such as country, alcohol consumption, smoking, age and which 
years the study was conducted. Another factor that has to be mentioned is the difference in 
the techniques that have been used in order to define HPV positivity. 
1.5 OROPHARYNGEAL, TONSILLAR, AND BASE OF TONGUE SQUAMOUS 
CELL CARCINOMA (OSCC, TSCC AND BOTSCC)  
Malignancies located in the oropharynx area represent 3-5% of all the cancers diagnosed 
each year in the Western world. It is estimated that each year 600.000 cases of HPV 
associated malignancies arise and of these 10% are due to OSCC, more specifically TSCC 
and BOTSCC. Historically, HNSCC as well as OSCC have mainly affected males. This is 
most likely due to the fact that smoking and alcohol consumption has, in the past, been 
higher among men than women. However, so far, HPV positive OSCC is also mainly a 
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male disease and around 80% of the cases occur in men
13, 163-165
.  It has also recently been 
suggested that men are more sensitive to oral HPV infection than women, since women 
more easily mount an immune response in their genital tract. Whether this hypothesis 
holds true or not, will have to be investigated further. An illustration of the oropharynx is 
given below in Figure 8. 
 
Figure 8: Anatomy of the oropharynx. 
1.5.1.1 Anatomy and histology of the oropharynx 
The oropharynx is a part of the head and neck region, which is located in the backside of 
the oral cavity and is in the middle of a region called the pharynx. The oropharynx can be 
divided into four sub-sites, which are distinct from each other. This includes the palatine 
tonsils, the base of the tongue, the soft palate and the pharyngeal walls, which are all 
covered by squamous epithelium.  
The histology of the normal oropharynx, also includes areas of “lymphoepithelium”. This 
is due to the fact that the squamous epithelium makes invaginations into the underlying 
lymphoid tissue and leading to the formation of structures called crypts. The majority of 
the crypts are found in tonsils with 10-30 per tonsils while their existence is less prominent 
(one or two) at the base of the tongue
13
. This area in the oropharynx including 
lymphoepithelium, consists of the palatine tonsils, the lingual tonsil and the 
nasopharyngeal tonsil including the adenoid pad and is called the Waldeyer’s ring or 
nasal-associated lymphoid tissue (NALT) and for details sees Figure 9. 
Notably, due to the structure of the epithelium 
and the invaginations tumors arising here 
usually metastasize very early and there are 
usually metastases in the lymph nodes prior to 
the discovery of the primary tumor, especially 
when it comes to small tumors
13
. 
Figure 9: The Waldeyer’s ring. 
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1.5.1.2 Oropharyngeal cancer classification and staging 
OSCC is well-characterized and there are classification systems and codes defining 
different OSCC sub-types. The standard classification system for specific localization of 
tumors is the International Classification of Diseases (ICD) system. In the table below a 
very simplified version of the classification used will be given in order for the reader to be 
able to follow. 
Different cancer types are also categorized according to their stage and based on the stage 
and other clinical or molecular characteristics of the tumor a treatment schedule can be 
designed, since tumor stage generally also has great prognostic significance. Clinical 
staging of the OSCC is made according to the TNM classification system (International 
Union Against Cancer (UICC)). According to the last updated version of the TNM system 
the stage of a tumor is based on: 
- Size of the primary tumor (T-stage) 
- Presence, size, number of metastasis to lymph nodes and localization to 
regional metastasis to lymph nodes (N-stage) 
- Presence of distant metastasis (M-stage) 
Finally after the definition of the T, N and M stages of the tumor the TNM-classification is 
divided into stages I to IV
166
. The different T, N and M stages and the tumor stage arising 
from the combination of them are presented in tables 1 and 2 in the next page. 
Table 1: TNM classification of OSCC according to the UICC, copied and modified from Näsman A.
167
. 
TNM classification Definition 
T 
TX Tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis In situ carcinoma 
T1 Size of tumor <2cm in greatest dimension 
T2 Size of tumor >2cm in greatest dimension 
T3 Size of tumor >4cm in greatest dimension 
T4a Moderately advanced local disease 
T4b Very advanced local disease 
   
N 
NX Regional lymph nodes cannot be assessed 
N0 No metastasis in regional node 
N1 Metastasis in a single ipsilateral lymph node, <3cm in greatest dimension 
N2a Metastasis in a single ipsilateral lymph node, >3cm in greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, <6cm in greatest dimension 
N2c Metastasis inbilateral or ipsilateral lymph nodes, <6cm in greatest dimension 
N3 Metastasis in a lymph node, >6cm in greatest dimension 
   
M 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
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Table 2: Staging (Stage I-IVb) according to TNM staging and classification according to UICC, copied from 
Näsman A.
167
. 
  T1 T2 T3 T4a T4b 
N0 I II III Iva Ivb 
N1 III III III Iva Ivb 
N2a Iva Iva Iva Iva Ivb 
N2b Iva Iva Iva Iva Ivb 
N2c Iva Iva Iva Iva Ivb 
N3 Ivb Ivb Ivb Ivb Ivb 
 
1.5.2 OSCC, TSCC, BOTSCC, HPV epidemiology and clinical outcome 
Each year in Sweden there are approximately 350 cases of OSCC and more than 90% of 
these cases are TSCC and BOTSCC
168
. Notably, the incidence of OSCC, more specifically 
the incidences of TSCC and BOTSCC have increased since the 1970s not only in Sweden, 
but also in many other Western countries
159, 165
. This is due to an increase of the HPV 
positive cases especially.  
In countries, where smoking has decreased, HPV-negative TSCC and BOTSCC have been 
shown to decrease, as is the case for HNSCC in general. In some cases there are 
differential trends with regard to smoking among men and women as well, complicating 
the picture. Nevertheless, OSCC is mainly a male disease, with male dominance both for 
HPV positive and HPV negative cancer.  
Notably, distinguishing HPV-positive from HPV-negative OSCC is of importance, since 
patients with HPV-positive TSCC and BOTSCC have higher 5-year disease free survival 
(DFS) than those with HPV-negative cancer (80% vs. 40% for HPV-positive and HPV-
negative cancers respectively).  
This has resulted in the scientific community now describing two different 
OSCC/TSCC/BOTSCC entities that would probably require different treatment strategies. 
Moreover, patients with HPV-positive TSCC and BOTSCC are frequently not heavy 
smokers or drinkers, when compared with patients with HPV-negative cancer and they are 
also younger (with a median age often <60 years of age). In addition, there are several 
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studies pointing out differences in the biological and molecular level of the two 
diseases
169-171
. It has been shown that in HPV-positive TSCC the mutation rate is lower 
compared to the HPV-negative ones
172
. In addition, p16
INK4a
 is generally up-regulated in 
HPV-positive OSCC compared to the HPV-negative OSCC. Furthermore, p53 is usually 
mutated in the negative cases while it is been degraded in the HPV-positive cases due to 
the function of E6 as mentioned previously, and this has been presented for cervical as 
well as head and neck cancer
173-175
. Differences have also been revealed in other 
molecules, such as microRNAs
176
.  
1.5.3 Treatment modalities for HNSCC and OSCC, TSCC and BOTSCC 
In the past, standard treatment for HNSCC was radiotherapy and/or surgery and for early 
stage tumors survival was fairly good
177, 178
. However, most HNSCCs are usually detected 
late and of higher stage and with poor prognosis, i.e. with a 40% 5-year DFS. This has led 
to intensification of treatment in the past decades with a somewhat increased survival, but 
also at the cost of increased side effects for the patients
178, 179
. Intensified treatment 
includes induction or concomitant chemotherapy and also hyperfractionated radiotherapy. 
In addition, in some cases Cetuximab is also administered, which is a monoclonal 
antibody used to block endothelial growth factor receptor (EGFR)
180, 181
.  
It is doubtful whether all patients with HPV-positive TSCC/BOTSCC need this intensified 
treatment, since in the past 80% of this category of patients survived with only 
conventional radiotherapy and surgery. However, to taper therapy, it is necessary to 
identify which patients will benefit from lesser treatment. To allow for a safer and more 
accurate selection of patients for de-intensified treatment, it is of importance to combine 
positive HPV status with additional prognostic biomarkers. The hunt for additional 
prognostic biomarkers is a main focus of this thesis. 
1.5.4 HPV positive status in OSCC/TSCC/BOTSCC 
The definition of HPV positive status has varied immensely in the literature with 4 or 5 
different definitions being used since the beginning of the HPV era and especially, with 
regard to OSCC/TSCC and BOTSCC. Initially, this was not given much importance. 
However, when the prognostic importance of HPV for TSCC and BOTSCC emerged then 
exactness has gradually become more important. 
Initially, e.g. HPV positive OSCC/TSCC/BOTSCC were mostly defined as 
overexpressing p16
INK4a
 and later on a definition of the p16 positivity was defined as 
overexpression in  >70 % of the malignant cells (p16+) or as being HPV DNA+. Since 
p16
INK4a
 was overexpressed in the majority of the HPV positive tumors, p16 
overexpression was used as a surrogate marker for the presence of HPV in numerous 
studies. This was also the case with the presence of HPV DNA. HPV DNA alone is a very 
good indication of HPV positivity of a tumor but it does not show active HPV infection. 
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The presence of HPV E6/E7 mRNA is of course more secure as being the sign of an active 
HPV infection and is the golden standard if one wants to assess HPV as a causative factor 
in a tumor
182
. However, monitoring mRNA has been more difficult and has been 
dependent on what samples possible to obtain. Originally, fresh frozen samples were 
necessary for determining presence of RNA. 
Throughout the years, many different detection methods have been used for identifying 
HPV in a tumor. The fact is that today neither HPV DNA nor p16
INK4a
 can alone stand as 
markers for active HPV infection. It has relatively recently been shown that the 
combination of positive HPV DNA (HPV DNA+) status alongside overexpression of 
p16
INK4a 
(p16+) easily determined in formalin fixed paraffin embedded (FFPE) samples, 
has almost the same sensitivity and specificity as determining presence of the golden 
standard i.e. HPV E6/E7mRNA
183, 184
. In this thesis, HPV-positive status has been 
determined as being both HPV DNA+ and overexpressing p16
INK4a
, i.e. HPV 
DNA+/p16+. That the definition of having an HPV positive status is not consistent 
throughout this thesis, which in retrospect is unfortunate reflects in many ways changes in 
the field so far. Hopefully, in the future the definition of HPV positive status will become 
more convergent and consistent throughout the scientific community.   
1.5.5 Prognosis and biomarkers: Where have we come? What do we miss? 
An important aspect in medicine is to be able to prevent a disease and another one is to be 
able to predict what the outcome of it will be. It is very important that the prognosis is 
robust enough so that the clinicians have the ability to decide on treatment regimes. In this 
direction, many prognostic biomarkers apart from the HPV and p16 status of the tumor 
have been studied for their importance in OSCC and many different ones have been 
proposed.   
Different tumor types overexpress different molecules and they are used in the clinic as 
prognostic biomarkers. Relatively specific biomarkers are e.g. p16
INK4a 
for cervical and 
oropharyngeal cancer
55, 185
, HER-2 for breast cancer
186
 and PSA for prostate cancer
187
.  
There are also more universal biomarkers that have been used and studied in many 
different cancer types. One such example is the use of counting tumor infiltrating 
lymphocytes (TILs). The immune system plays an important role in combating tumors and 
infiltration of lymphocytes and especially CD8+ and CD4+ TILs have been used as 
biomarkers in various tumor types such as anal
188
, breast
189
, lung
190
, urothelial 
carcinoma
191
, head and neck carcinoma
192, 193
 and others. Furthermore, different models 
have been proposed and immunoscore, where various types of TILs are investigated with 
regard to their number and their location in or out of the tumor and an algorithm has been 
used to calculate the prognostic significance of the findings
194
.  
HLA class I expression has also been investigated in various tumor types such as breast, 
lung, ovarian, cervical and head neck cancer and in many tumor types HLA class I 
expression has been found to be downregulated
195-200
. Moreover, downregulation of HLA 
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class I expression has also been linked with a poor outcome in various tumors such as 
ovarian and head neck cancer
198, 201
. The investigation of specific HLA alleles has also 
been performed and it has been shown e.g. that presence of the HLA-A*02 allele is 
associated with worse prognosis in ovarian cancer of stage III and IV and also a 
correlation with prognosis has been demonstrated in prostate cancer and malignant 
melanoma
202, 203
. 
Evaluating protein expression by immunohistochemistry on formalin fixed and paraffin 
embedded (FFPE) tissues has the advantage of easily being performed in the pathology 
unit at the clinic and is also a reliable and straightforward technique. Recently, several 
studies by others and us have focused on finding prognostic markers for TSCC and 
BOTSCC. Well-studied and confirmed biomarkers from different studies are p16, which is 
often used as a surrogate marker of HPV infection and co-expression with Ki-67, EGFR, 
LRIG1
204-206
.   
In this thesis, the focus is on biomarkers related to the immune system. Studying the 
infiltration of TSCC and BOTSCC biopsies by CD8+ and CD4+ TILs was an obvious 
choice, since this has been extensively studied on other tumor types as described 
previously.  
Furthermore, since both E5 and E7 mRNA have the capacity to regulate HLA class I, 
studying expression of HLA class I was also intriguing in relation to prognostic 
significance. The fact that we also looked at the expression of HLA class II was based on 
findings that it can be observed in cervical cancer, despite the fact that it is normally not 
expressed in epithelial cells
207-209
. In addition, its expression has been linked with both 
good and poor prognosis for many malignancies 
210-212
 and because there was no such 
study on TSCC/BOTSCC, it was an obvious choice as well.   
HLA-A*02, was also an interesting candidate, since as mentioned above HLA-A2 has 
shown prognostic significance for other malignancies and is a very common allele in the 
Scandinavian population. Finally, based on our findings on HLA class I we decided to 
look at some of the components of the antigen processing machinery (APM) and examine 
if they were in any way related to HLA expression, to each other and examine their 
prognostic significance. 
After accumulating information on many markers, it was obvious that using single 
biomarkers were not optimal to predict clinical outcome for all patients. For this purpose 
we attempted to combine different biomarkers, which have high specificity and sensitivity 
in a single algorithm in order to be able to identify the best combination that could lead to 
a safer and more accurate prognosis for individual patients. This way it might be easier for 
the clinicians to decide on a different regime of treatment and a possible de-escalation of 
it.  
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2 AIMS 
 To investigate the role of HLA class I and II antigen expression in a large cohort 
of OSCC in relation to the HPV status of the tumor and the clinical outcome. 
(Paper I) 
 
 To study the role and the prognostic significance of CD8+ and CD4+ tumor 
infiltrating lymphocytes (TILs) in relation to HPV and the clinical outcome of 
patients with TSCC and BOTSCC. (Paper II) 
 
 To investigate the role of the HLA-A02* allele in relation to HPV an clinical 
outcome of patients with TSCC and BOTSCC. (Paper III) 
 
 To investigate molecular biomarkers mainly associated with antigen processing 
such as TAP1, TAP2 and the immunoproteasomal subunits LMP2, LMP7 and 
LMP10 in TSCC and BOTSCC and their expression in correlation to HPV status 
and clinical outcome of the patietns. (Paper IV and V) 
 
 To combine information and prognostic significance of some of the 
aforementioned biomarkers together with clinical characteristics of the patients in 
one single algorithm allowing for prediction of the clinical outcome of patients 
with HPV-positive tonsillar and base of tongue cancer. (Paper VI) 
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3 MATERIALS AND METHODS 
3.1 PATIENTS, MATERIALS AND DESIGN OF THE STUDIES 
3.1.1 Patients and biopsies and ethical permissions 
The patients included in the studies of this thesis will be presented separately for each 
study below. All the studies conducted and included in this thesis were conducted 
according to the ethical permissions 2003/507, 2005/431-31/4, 2005/1330-3, and 
2009/1278-31/4 from the Regional ethical committee at Karolinska Institutet, Stockholm, 
Sweden.  
Paper I. In this study, 385 patients were diagnosed with TSCC (ICD-10 C09.0-9) or 
BOTSCC (ICD-10 C01.9) at Karolinska Institutet in Stockholm between 2000 and 2007. 
203 with TSCC and 77 with BOTSCC were treated with curative intent and had available 
pre-treatment biopsies to be included in the study.  
Paper II. In this study, all patients with OSCC defined by the ICD-10 codes C09.0-9; 
C01.9; C05.1-9; C10.0-9 and diagnosed between 2000 and 2009 were included. Patients 
with C09.0-9 and C01.9 were diagnosed between January 2000 – September 2009 and 
patients with C05.1-9 and C10.0-9 between January 2000 – January 2009. All patient 
records were examined and patient characteristics and clinical outcome were obtained to 
be used for the study. 
Paper III. Between 2000 and 2009, 445 patients were diagnosed with TSCC and 
BOTSCC (ICD-10 codes: C09 and C01.9 respectively) at the Karolinska University 
Hospital. Of these 425 patients with biopsies previously tested for HPV DNA and with 
sufficient material to test for HLA-A*02 were included. 383 of these patients were treated 
with the intention to cure and were included in the survival analysis.  
Paper IV. During 2000-2007, 385 patients were diagnosed with TSCC (ICD-10 C09.0-9) 
or BOTSCC (ICD-10 C01.9) at Karolinska Institutet in Stockholm. 278 patients with 
available pre-treatment biopsies previously tested for HPV DNA and with sufficient 
material included in the study. 
Paper V. In this study, two patient cohorts were included. One with TSCC and one with 
BOTSCC, with 151 patients in total, all treated at the Karolinska University Hospital. The 
first sample set consisted of 78 TSCC (ICD-10 C09.0-9) from patients diagnosed from 
2000 to 2006 and pre-treatment biopsies available. This set included 48 HPV DNA-
positive and 30 HPV DNA-negative TSCC derived from a set of 83 TSCC samples 
included in the analysis for HLA class I, but with 5 tumours excluded due to lack of 
material. The second set consisted of all 73 BOTSCC samples, 53 HPV DNA-positive and 
20 HPV DNA-negative diagnosed between 2000 and 2007 and with available pre-
treatment biopsied. 66 of these were treated with curative intent.   
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Paper VI. Data were collected on patients diagnosed during 2000–2011 with HPV DNA+ 
tumour biopsies, 308 with TSCC (ICD-10 code: C09.0-9) and 112 with BOTSCC (ICD-10 
code C01.9), at the Karolinska University Hospital. The study was initiated on a training 
cohort of 197 patients diagnosed during 2000–2007, and validated on a cohort of 118 
patients from 2008–2011. Only curatively treated patients with HPV DNA+/p16+ FFPEs 
were included.  
3.2 METHODOLOGY AND TECHNIQUES 
In this thesis, the techniques and methods utilized were DNA extraction, PCR and 
immunohistochemistry. Below each one of these will be explained and presented in more 
detail. It has to be mentioned that the determination of the HPV status of the tumors was 
conducted earlier (2000-2007) by using conventional PCR and later (2007 onwards) 
mainly by a bead-based multiplex assay. 
3.2.1 DNA extraction 
DNA was extracted for all the applications in this thesis by using the High Pure RNA 
extraction kit (Roche, Molecular Biochemicals, Mannheim, Germany). The procedure 
followed was the one suggested from the manufacturer with the exception that the 
DNAase treatment step was excluded. The reason for extracting DNA with an RNA 
extraction kit was that we wanted to maintain the possibility to also examine for RNA 
from the same sample. Blank controls were used in order to excluded cross-contamination 
of HPV DNA and HLA-A*02 between samples. 
3.2.2 Conventional and Multiplex PCR for HPV detection 
Briefly, for the conventional detection of HPV DNA the commonly used consensus primer 
sets GP5+/GP6+ and CPI/CPIIG and also the primers specific for HPV 16 were used as 
has been described previously
165
. The coverage of these primers includes all known HR-
HPV types. The GP5+/GP6+ primers amplifies the L1 ORF giving rise to an amplicon of 
approximately 130 to 150bp while the other set of primers recognizes the E1 ORF and the 
amplicon is around 190bp. The HPV type specific primers target the HPV 16 E6 Open 
Reading Frame (ORF). The samples that were positive for HPV other than HPV 16 were 
subsequently subjected to sequencing for type determination. The amplicons were with 
this method evaluated by gel electrophoresis. 
For samples from 2008 and onwards a Luminex bead-based multiplex HPV assay was 
used for the HPV status determination of the tumors and this technique is described in 
detail elsewhere
179
. This assay allows for increased sensitivity and has the ability to detect 
and identify up to 27 different types at once.  
Furthermore, the Multiplex PCR was used to reevaluate some of the samples, earlier tested 
with conventional PCR, both for having consistency and also for validating the method 
itself.  
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In this assay, a set of variants of the GP5+/GP6+ primers were designed
213
, to allow for a 
similar sensitivity for all the included HPV types. With this primer set, a more equal 
amplification was obtained for all the HR HPV types and the sensitivity was 10 to 100 
copies
213
. In addition, primers for human DNA b-globin were included as a control for 
amplifiable cellular DNA. All the reverse primers were biotinylated, which allowed for a 
detection step later on in the assay as described below. 
So, how does the Luminex assay work? In the MagPix instrument from Luminex up to 50 
different magnetic beads can be used, all with different colors that can be identified by 
lasers in the MagPix machine. To each of the specific beads, which in our case are 28 (27 
HPV types and b-globin and E6 of HPV16), a specific probe is coupled. Each of these 
different probes is specific only for one of the analyzed HPV types. In the assay, the PCR 
amplicons are denatured and mixed with the bead mixture at a specific hybridization 
temperature, in order for the probes that are coupled on the beads to be hybridized with the 
PCR amplicons. After this incubation, all primers and PCR amplicons that have not bound 
to the probes are washed away and the hybridized products are then subjected to a step 
where fluorescent streptavidin binds to the biotinylated primers. After all these steps, the 
beads are analyzed on a magnetic plate. As mentioned before two lasers are used and each 
bead is identified by its color and the amount of amplicons bound to it is measured by 
analysis of the fluorescent streptavidin. The output is given as Median Fluorescent 
Intensity (MFI) for each bead type. HPV DNA positive is below denoted HPV DNA+, 
while HPV DNA negative denoted as HPV DNA-. 
3.2.3 PCR for HLA-A*02 amplification from FFPE  
Conventional PCR was used for the detection of the HLA-A*02 allele in paper III. The 
method for amplifying the allele from FFPE biopsies is described in detail elsewhere
214, 
215
. HLA-A*02 primers (forward A*577LL and reverse A*503invLL) were designed in 
order to amplify the HLA-A*02 exon 2, with exception of the A*020109, 0248, 0250, 
0255 alleles, which have been found to be uncommon in the Swedish population, and have 
been described previously
202
. This method has the advantage of being able to perform in 
FFPE material and blood samples from the patients are thus not necessary to obtain. It thus 
allows for retrospective studies without the need for additional samples. 
The PCR reaction and program used for the amplification of the allele are given in the 
next page: 
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PCR reaction 
 5ul 10X PCR Buffer PE 
 8ul DNTPs (1.25 mM/dNTP) 
 3ul MgCl2 (25mM) 
 2ul forward primer (10pmol/ul) 
 2ul reverse primer (10pmol/ul) 
 0.4ul Taq polymerase 
 2.5ul sample DNA (50ng) 
 dH2O until total volume of 50ul 
PCR program 
 94oC   4 min 1 hold 
 94oC  30 sec 40 cycles 
56
o
C  30 sec 
72
o
C  45 sec  
 72oC  5 mis 1 hold 
 4oC  on hold 
 
3.2.4 Immunohistochemistry 
As mentioned above, testing of all the different biomarkers in this thesis, except for HLA-
A*02, was mainly done by immunohistochemistry (IHC). Different antibodies were used 
for each marker, but the immunohistochemistry protocol was similar for each biomarker.  
For detection of CD8+ and CD4+ TILs the streptavidin-biotin peroxidase method was 
used on 4µm formalin fixed, paraffin embedded (FFPE) sections. The mouse monoclonal 
antibodies anti-CD8 (clone 4B11, dilution 1:40) and anti-CD4 (clone 1F6, dilution 1:40) 
both from Novocastra Laboratories were used. All sections were subsequently incubated 
with biotinylated secondary antibody (1:200, Vector Laboratories, Burlingame, CA, 
U.S.A.). This was followed by incubation with the avidin-biotin-complex-PO using the 
VECTASTATIN® Elite® ABC kit (Vector Laboratories) and developed with DAB. 
For detection of HLA class I and II, heavy chains the mouse monoclonal antibodies (mAb) 
HCA-2 and HC-10 were utilized. HCA2 recognizes most HLA-A and HC-10 most HLA-
B and -C heavy chains, with some overlaps- The latter was obvious in paper IV and 
correlation to clinical outcome was as evaluated for both HC10 and HCA2 expression. 
HLA class II antigens were analyzed using mAb LGII-612.14 which recognizes HLA-DR 
–DQ and DP, but not other HLA class II antigens. The protocol used for 
immunohistochemical staining was similar to as that described for CD8+ and CD4+ TILs. 
HLA-DR –DQ and DP, but not other HLA class II antigens). The protocol used for 
staining was similar to as that described for CD8+ and CD4+ TILs. 
For the different APM components that were analyzed in this thesis, the following 
antibodies were used: for TAP1, rabbit polyclonal H-300; for TAP2, rabbit polyclonal 
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H210, both from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA); for LMP2, rabbit 
polyclonal antibody ab3328; for LMP7, ab3329, both from Abcam (Cambridge, United 
Kingdom). As secondary antibodies, BA-1000 anti-rabbit (1:200) and BA-2000 anti-
mouse (1:200) both from Vector Laboratories (Burlingame, CA, USA) were used and 
the protocol was the same as described above.  
3.2.4.1 Evaluation of immunohistochemistry slides 
Despite the fact that the IHC protocol was similar for all the studies included in the thesis, 
the evaluation criteria were different in some cases and here this will be described in more 
detail.  
For the evaluation of CD8+ and CD4+ TILs counts, 5 microscopic fields in a 
magnification of 40X were used and at least two independent researchers counted the 
infiltrating lymphocytes.  
For the evaluation of HLA class I and II expression, both intensity of staining and 
percentage of the stained malignant cells were evaluated in comparison to the surrounding 
normal tissue, stroma and immune cells. The intensity of staining was categorized as 
“absent”, “weak” or as “normal/strong” staining. In addition, the percentage of stained 
malignant cells was defined on a four tier scale and this was 0%, 1-25%, 26-50%, 51-75% 
and 76 -100%. Notably, in some cases HLA staining could vary within tumors from weak 
to normal or strong. In that case the part that resembled the most was used as an intensity 
score. This could be a result of different cell clonally selected populations within the same 
tumor or HPV could have something to do with that. However, it is difficult to comment 
on that. One could argue that staining is not a safe way to go here but an absent HLA 
expression was of absolute absence and weak was always in between the two categories.  
The APM components that were examined as potential prognostic biomarkers in this 
thesis were evaluated both for nuclear and cytoplasmic compartments. The reason for the 
discrepancy in evaluation between different markers was mainly due to the fact that 
different staining patterns were observed between the tumors. Thus it was reasonable to 
evaluate both staining patterns. Thus, intensity and percentage of staining was also 
evaluated but separately for each of the compartments. The intensity was scored as 
“absent”, “weak”, “medium” and “strong/normal”. The percentage was scored on a four 
tiered scale: 0%, 1-25%, 26-50%, 51-75% and 76 -100% of stained malignant cells. Of 
course, one could still argue about the evaluation and the uncertainty but it is quite easy for 
someone to distinguish the differences in the figures presented in papers IV and V.  
3.2.5 Statistical analysis and data interpretation 
Statistics and analysis of the data is very useful because it gives us the mathematics and 
values to evaluate the possible significance of the accumulated data. The statistical 
analysis and tests that were used throughout this thesis are presented below. 
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The Wilcoxon-Mann-Whitney test was used in order to test for differences in continuous 
and ordered categorical variables as the ones presented in paper I. Fisher’s exact test and 
Pearson Chi-square test were used for unordered categorical variables. Student t-test or 
independent samples t-test was used for comparison of mean values between groups. 
Spearman rank correlation test was used for the comparison of expression of the different 
APM components.  
Clinical outcome and survival of patients was measured in years after diagnosis 
until the occurrence of an event or 3 years after diagnosis where censoring of patients was 
applied. An event was defined as death due to any cause even non-related to disease 
(Overall survival, OS), death of patients by disease (Disease Specific Survival, DSS) or 
relapse of the disease (Disease Free Survival, DFS). Patients that died without any obvious 
signs of the disease were considered censored in DSS and patients that died without any 
prior relapse were censored at day 0 in DFS. Kaplan Meier curves were used for survival 
estimates of OS, DSS and DFS and differences in the survival were calculated by using 
the log-rank test. The Cox-proportional hazards model was used for calculation of the 
unadjusted and adjusted hazard ratios. More advanced statistics were used for the 
development and building of the prediction model in paper IV and these are analyzed in 
detail in the aforementioned paper.   
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4 RESULTS AND DISCUSSION 
4.1 CD8+ AND CD4+ TILS IN HPV POSITIVE AND NEGATIVE TSCC AND 
BOTSCC AND PROGNOSIS (PAPER I) 
Aim: To study the role of the CD8+ and CD4+ TILs in TSCC and BOTSCC in relation to 
HPV status of the tumor and the clinical outcome of the patients. 
Results: In total 280 patients diagnosed 2000-2007 with TSCC (203 patients) and 
BOTSCC (77 patients) that had available biopsies and treated with curative intent were 
included in the study. All of the samples had previously been tested for HPV DNA and 
p16 expression. Immunohistochemistry was applied on sections for detection of CD8+ and 
CD4+ TILs. 
Of the 280 tumors, 79% were HPV DNA+, with HPV 16 being the dominant type (94%). 
In addition, patients with HPV DNA+ TSCC were generally younger and had lower T-
stages when compared to those with HPV DNA- tumors. Furthermore, the majority of the 
patients were males without any difference in sex distribution between TSCC and 
BOTSCC. Patients with HPV DNA+ BOTSCC had higher nodal stage and T-stage when 
compared with patients with HPV DNA- tumors.  
HPV DNA+ tumors were found to be more frequently p16+ as compared to the HPV 
DNA- ones (82% vs. 8%). The numbers of the CD8+ and CD4+ TILs were possible to 
evaluate in 98% and 96% of the tumors respectively, and the loss of adequate samples was 
due to the fact that there was very little material left. There were significantly higher 
numbers of CD8+ TILs in the HPV DNA+ tumors compared to the negative ones (median 
was 36.0 and 6.2 respectively, MWW test, p<0.001). The same was true for the CD4+ 
TILs (median 13.3 and 7.3 respectively, MWW test, p=0.001).  
A high CD8+ TIL count but not CD4+ count was found to be a favorable prognostic factor 
for patients with HPV DNA+ and HPV DNA+/p16+ tumors. To be able to evaluate the 
samples, patients were divided into four quartiles depending on their TIL counts. Upon 
evaluation patients within the 3 quartiles with the highest counts had a significantly better 
prognosis with regard to 3-year OS and DFS as compared to those in the quartile with the 
lowest counts (Figure 10). The same trends were observed for HPV DNA- tumors but 
statistical significance was obtained only for OS and the 4
th
 quartile with the highest 
counts. Notably, also the numbers of TILs in the different quartiles were lower for the 
HPV DNA- samples. 
For CD4+ TIL counts, there was no effect on the clinical outcome of patients with HPV 
DNA+ and HPV DNA+/p16+ tumors. There was a tendency for better outcome of patients 
with HPV DNA- and HPV DNA-/p16- tumors but no statistical significance was obtained. 
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Figure 10: Kaplan Meier curves showing OS and DFS of patients with HPV DNA+ TSCC (A and B 
respectively) and HPV DNA+/p16+ TSCC (C and D respectively). Data have been stratified for counts of 
CD8+ TILs and they have been divided into 4 quartiles (The figure from Paper I, with permission from the 
publisher). 
Discussion: In this study CD8+ and CD4+ TIL counts were investigated with regard to 
their potential as prognostic factors for clinical outcome of patients with HPV DNA+ and 
HPV DNA- TSCC and BOTSCC. We found that 79% of the samples were HPV DNA+ 
and that in general HPV DNA+ tumors were more infiltrated and displayed higher counts 
of CD8+ TILs than the HPV DNA- ones. Since HPV status of tumor defines two different 
tumor entities the two groups were studied separately and notably the mean/median CD8+ 
TIL count was different for the two groups. For patients with HPV DNA+ and HPV 
DNA+/p16+ tumors, the three highest quartiles of CD8+ TIL counts correlated with an 
increased survival of patients, while for HPV DNA- tumors this was only true for the 
highest quartile. In the latter group the CD8+ count of the highest quartile was similar to 
that of the first quartile of the ones with HPV DNA+ tumors.   
CD4+ TIL counts were not correlated with survival in any of the groups although, there 
was a tendency for better clinical outcome of patients with HPV DNA- tumors and HPV 
DNA-/p16- tumors and high CD4+ TIL counts.  
The fact that a high CD8+ TIL count was correlated with a high survival of patients was in 
line with a pilot study that had previously been performed by our group
193
. In addition, 
there are also other studies showing the same difference obtained between the HPV DNA+ 
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and HPV DNA+/p16+ and the HPV DNA- and p16- groups with regard to survival in 
other malignancies such as cervical cancer and OSCC. The higher numbers of CD8+ TILs 
in HPV DNA+ tumors and/or HPV DNA+/p16+ tumors are also in line with in vitro 
studies indicating the importance of T-cell responses for HPV positive OSCC tumors
140
. 
Recent studies have also confirmed the significance of CD8+ TILs with regard to survival 
of patients with HPV positive HNSCC and they have also shown the increased infiltration 
that we show here
216
. They have looked at CD8+ TILs in head and neck cancer in general 
and the result of this study was similar to what we found, showing that CD8+TILs is 
indeed a very good biomarker for prognosis of the patients with clinical outcome and for 
possible stratification regarding treatment. Apart from the tumor infiltrating CD8+ TILs 
people have looked at the existence of these cells in the tumor microenvironment and they 
have shown in a recent study by Oguejiofor et al. that infiltration of the surrounding 
stroma by CD8+ TILs is associated with increased survival of patients with OSCC
217
. 
Thus, it becomes obvious that the immune system indeed plays a major role and 
infiltrating lymphocytes contribute to the better survival of patients. 
Having high counts of CD8+ infiltrating the tumors suggests that these cells have the 
potential to be active against the tumor, despite the fact that we have pretreatment 
biopsies. It is worth assuming that upon treatment the pool of intracellular peptides being 
presented is increasing and the fact that we have more infiltration in the HPV DNA+ 
group is probably due to the fact that we have foreign antigens being presented. This 
allows for easier recognition by CD8+ TILs allowing for increased activity. This 
assumption can be strengthened further from a study showing that a higher proportion of 
CD8+ TILs deriving from HPV DNA+ HNSCC samples have the capacity to produce 
IFN-gamma and IL-17 upon in vitro stimulation
218
. 
The number of CD4+ TILs did not show any significant correlation to survival of patients 
with HPV DNA+ tumors but in patients with HPV DNA- tumors and HPV DNA- p16- 
tumors a higher infiltration with CD4+ TILs tended to result in a better clinical outcome of 
these patients. Other studies testing for CD3+ TILs which is a marker of T cells in general 
(thus including both CD4+ and CD8+ TILs) have shown similar data with regard to 
survival of patients with HPV DNA- and HPV DNA-/p16- tumors but no association has 
been revealed with HPV positive OSCC
216
.  
Conclusion: Patients with HPV DNA+ and/or HPV DNA+/ p16+ tumors with a high 
infiltration of CD8+ TILs generally have a better clinical outcome than those with tumors 
with low infiltration of CD8+ TILs. The data therefore suggests that CD8+ TILs are an 
additional prognostic factor that could be used together with the HPV status of the tumor 
in order for better prediction of the outcome of the patients when selecting for studies on 
more individualized therapy.   
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4.2 HLA CLASS I AND II EXPRESSION IN OSCC IN RELATION TO HPV 
STATUS AND CLINICAL OUTCOME (PAPER II) 
Aim: To extend a previous study on HLA class I expression and also investigate the role 
of the classical HLA class I and II antigens in a large cohort of OSCC in relation to HPV 
status and the clinical outcome of the patients. 
Results:  In total 439 patients diagnosed with OSCC that were treated with curative intent 
and had available pre-treatment biopsies were included in the analysis and of these, 
303/439 (69%) were HPV DNA+. The analysis of HLA class I and class II expression was 
performed both for HPV DNA+ and HPV DNA- and for HPV DNA+/p16+ and HPV 
DNA-/p16- tumors. 
Patients with HPV DNA+ tumors had in general a better OS, DSS and DFS when 
compared with HPV DNA- and this was true in a multivariate analysis as well where age, 
stage and tumor localization were included and were therefore analyzed separately. 
Patients with HPV DNA+ OSCC were more often younger (p<0.001), non-smokers 
(p<0.001) and they generally presented smaller tumors (p=0.009), greater nodal stage 
(p<0.001) and a higher tumor stage (p=0.009). 
In this study, in patients with HPV DNA+ tumors we showed that absence of HLA A, B 
and C, expression, measured as intensity of membranous staining by IHC with the 
antibodies HC2 and HC10 was correlated with a high OS, DFS and DSS and this was 
irrespective of the treatment regime used. More specifically, patients with absence of HLA 
class I and HPV DNA+ tumors had a very high survival, while the opposite was s true for 
strong intensity and weak intensity presented an intermediate survival (HC10: OS 
p=0.009, DFS p=0.003, DSS p=0.021) (Figure 11). Survival data were also analyzed in a 
multivariate manner adjusted for sex, age, stage and tumor localization and still patients 
with HPV positive OSCC and absence of HLA class I staining presented a better DFS, 
DSS and OS (HC10: all disease free, p=0.040 and p=0.024 respectively).  
Similar data were obtained for HPV DNA+/p16+ tumors, but here statistical significance 
was obtained only for DFS. 
In contrast, in patients with HPV DNA- tumors, absent HLA class I expression was 
correlated to a worse survival of these patients, while high HLA class I correlated to a 
better clinical outcome. 
HLA class II expression, was not found to be correlated to survival in patients with HPV 
DNA+ tumors, but a high HLA class II expression was found to be correlated with 
increased DSS and OS, but not DFS in patients with HPV DNA- tumors.   
In general, HLA class I expression was generally lower in HPV DNA+ OSCC and HLA 
class II was more often higher as compared to the HPV DNA- cases and these differences 
were significant. (p=0.009 and p<0.001 for intensity of staining). 
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Figure 11: Kaplan-Meier curves showing disease-free survival (DFS), disease-specific survival (DSS) and 
overall survival (OS) for patients with HPV DNA+ oropharyngeal squamous cell carcinoma (OSCC) in 
relation to HLA class I expression. (With permission of the publisher) (A) DFS, (B) DSS, (C) OS, all 
stratified for HCA-2 intensity (D) DFS, (E) DSS, and (F) OS, all stratified for HC-10 intensity. HPVDNA+ 
OSCC and absence of HLA class I showed a significantly better clinical outcome than tumors with strong 
HLA class I intensity.,  Weak intensity staining revealed an intermediate survival (HCA-2: DFS p<0.001; 
DSS p=0.060; OS p=0.022; HC-10: DFS p=0.003, DSS p=0.021 and OS p=0.009,log-rank test).  
 
Discussion: The fact that absence of HLA class I expression was associated with a very 
high survival of patients with HPV DNA+ OSCC was in line with previous data from the 
pilot study where similar findings were obtained in a smaller cohort of TSCC, but 
paradoxically from an immunological point of view. In addition, it is in contrast with what 
others have shown and a recent study looking at penile carcinoma and HPV, showed that 
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partial loss of HLA class I expression was associated with poor survival
219
. Why absence 
of HLA is associated with increased survival of patients with HPV DNA+ OSCC remains 
to be elucidated. There are however differences in our tumor model and those of others. In 
HPV positive tumors, E5 has the potential to repress HLA expression and the absence of 
HLA class I expression in some of the HPV DNA+ tumors could be a result of a 
prominent viral action. Also E7 has been demonstrated to down regulate HLA class I 
expression. HLA class I down regulation could be of benefit for the virus in this way 
avoiding immune recognition during infection. 
The finding that patients with HPV DNA+ tumors with absent HLA class I expression do 
very well, we hypothesize may depend on the fact that upon radiotherapy (RT) the pool of 
antigenic peptides is increased and an abrogation of the suppression of HLA class I 
expression. The presence of increased HLA class I expression and presentation, leading to 
improved immune recognition and better prognosis. Experimentally, it has been 
previously shown that RT can cause upregulation of HLA class I expression in cervical 
and myeloma cell lines
220
, and recently, data by Linnea Haeggblom in our group suggest 
that HLA class I expression is increased in HPV positive OSCC cell lines upon RT with 
doses around 10 Gy (unpublished). There are of course other studies showing that HLA 
class I downregulation may be due to viral integration within the HLA loci
221
. Thus, there 
are a number of possibilities on why absence of HLA class I still can be associated with 
increased survival of patients with HPV DNA+ OSCC, and this still has to be elucidated 
further.  
Clinical outcome was also examined according to which type of therapy was given. For 
patients with HPV DNA+ tumors and absent/weak of HLA class I expression, there was 
no difference in OS, DFS or DSS, irrespective of whether the patients had received RT 
alone or chemoradiotherapy (Figure 12). However, for patients with HPV DNA+ tumors 
with strong HLA class I expression, there was a significantly better survival (OS, DFS and 
DSS) for patients that had received chemoradiotherapy (CRT) when compared to RT 
alone. However, there may have been selection bias for more patients receiving only RT 
than CRT and having poor prognosis, which could possibly be the answer for the 
difference presented in the group of patients with strong HLA class I staining.  
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Figure 12: Kaplan-Meier curves by using the log rank test, for DSS of patients with HPVDNA+ OSCC and 
known HLA class I expression stratified for different treatment modalities. (A) DSS in HPVDNA+ OSCC, 
absent HCA-2 intensity and stratified for RT and CRT, (B) DSS in HPVDNA+ OSCC, weak HCA-2 
intensity and stratification for RT and CRT, (C) DSS in HPVDNA+ OSCC, strong HCA-2 intensity stratified 
for  RT and CRT (D) DSS in HPVDNA+ OSCC with absent HLA class I (HC-10) intensity stratified for RT 
and CRT (E) DSS in HPVDNA+ OSCC with weak HLA class I  (HC-10) intensity stratified for RT and 
CRT, (F) DSS in HPVDNA + OSCC with strong HLA class I (HC-10) intensity stratified for RT and CRT. 
Conclusion: Patients with HPV DNA+ tumors and absence of HLA class I expression 
have a better DFS, DSS and OS independent of what treatment they have received when 
compared to those with strong HLA class I intensity staining or those with HPV DNA- 
tumors. In contrast, for patients with HPV DNA- tumors strong HLA class I intensity 
expression was associated with increased survival. HLA class II expression did not show 
any correlation to survival.  
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4.3 HLA-A*02 IN RELATION TO HPV STATUS AND CLINICAL OUTCOME IN 
TSCC AND BOTSCC (PAPER III) 
Aim: To examine HLA-A*02 as a prognostic factor in TSCC and BOTSCC in relation to 
HPV status 
Results: Of the 445 patients that were diagnosed with TSCC and BOTSCC between 2000 
and 2009 at the Karolinska University Hospital, 425 patients (307 TSCC and 118 
BOTSCC) had available pretreatment biopsies and received curative treatment. These 
patients were included in the analysis. 
Patients with HPV DNA+ tumors were younger than those with HPV DNA- ones. HLA-
A*02 was present in almost 50% of the samples with 47% in the HPV DNA+ group and 
53% in the HPV DNA- group. There were no correlation between the frequency of having 
an HLA-A*02 allele depending on HPV status of the tumor or the gender of the patients 
(p=0.326 and p=0.744, respectively). In addition, there was no difference in the frequency 
of the HLA-A*02 allele with regard to tumor stage, nodal stage and distant metastasis for 
the whole group of patients irrespective of the HPV status. 
Absence of HLA-A*02 was correlated with a better 3-year DFS for the whole group of 
patients (p=0.046) and also for the HPV DNA+ group (p=0.016) but not for the HPV 
DNA- group (p=0.968) (data not shown and Figure 9). When the analysis was conducted 
separately for males and females, absence of HLA-A*02 was correlated to a better 
survival for males in the whole group (p=0.004) and only for males in the HPV DNA+ 
group (p=0.003). In a multivariate analysis by using Cox regression model, separately for 
HPV DNA+ and HPV DNA- groups, in the HPV DNA+ group absence of HLA-A*02 and 
lower age was still correlated with increased DFS of the patients (p=0.036 and p=0.003). 
There was no correlation in the HPV DNA- group and no correlation was found with 
regard to OS for none of the groups (Figure 13). 
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Figure 13: Kaplan Meier curves for DFS (A-C) and OS (D-F) of patients with TSCC and BOTSCC, 
presented for the whole group (A,D), HPV DNA + cases (BE) HPV DNA- cases (CF). 
Discussion: In this study presence of HLA-A*02 was around 50% and similar in patients 
with HPV positive and negative tumors, indicating that there is no specific sensitivity to 
the development of HPV positive tumors depending on HLA-A*02 status. Furthermore, 
the frequency of HLA-A*02 was high in this study, which could be expected since in 
Scandinavian population it has been reported to be 58% for the phenotype.  
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Absence of HLA-A*02 was correlated with a significantly better DFS for the whole group 
and for the HPV DNA+ group of patients and in males with HPV DNA+ tumors. This was 
in concordance with what has been previously shown for ovarian cancer, prostate cancer 
and malignant melanoma
202, 203
. That this was not the case for the HPV DNA- group and 
for females with HPV positive and also HPV DNA- tumors is probably mainly attributed 
to the low numbers of patients in these categories. Furthermore, there were no differences 
with regard to OS and this is probably due to the fact that OS is influenced by other factors 
apart from the disease itself or other causes that may lead to death. 
Conclusion: Presence of HLA-A*02 was similar in frequency between patients with HPV 
DNA+ and HPV DNA- TSCC and BOTSCC. In addition, presence of HLA-A*02 was a 
negative prognostic factor for patients with HPV DNA+ tumors. 
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4.4 LMP10 EXPRESSION IN RELATION TO HPV STATUS AND CLINICAL 
OUTCOME IN TSCC AND BOTSCC (PAPER V) 
Aim: To examine LMP10 expression in HPV DNA+ and HPV DNA- TSCC and 
BOTSCC in relation to clinical outcome. 
Results: In total 278 patients with TSCC and BOTSCC that were diagnosed between 2000 
and 2007 and had available biopsies and were treated with curative intent were included in 
the study. Of the tumor biopsies, 207/278 (74%) were HPV DNA+. As described 
previously patients with HPV DNA+ tumors were younger than those with HPV DNA- 
tumors (p<0.001). LMP10 was evaluated with regard to fraction of the cells stained as 
well as intensity staining in the cytoplasm and in the nucleus. The fraction of cells stained 
in the cytoplasm was relatively higher in the HPV DNA+ group as compared to the HPV 
DNA- group of tumors (p=0.033) apart from that no major differences with regard to 
LMP10 cytoplasmic staining were observed between HPV DNA+ and HPV DNA- 
tumors. 
Absent/ low fraction of positively stained cells for LMP10 nuclear staining was 
associated with a better 3-year DFS of patients with HPV DNA+ cancer but this was not 
true for patients with HPV DNA- cancer (p=0.005, p=0.688, respectively). No significant 
difference was observed with regard to OS in any of the patient groups. Moreover, 
absence as compared to presence of nuclear LMP 10 staining was also associated with a 
better DFS for individuals with HPV DNA+ cancer but not for those with HPV DNA- 
cancer (p=0.037, p=0.473, respectively) (Figure 14). Performing a multivariate Cox- 
regression analysis patients with HPV DNA+ or HPV DNA- tumors, including either 
fraction of stained positive cells in the nucleus, or intensity of nuclear staining together 
with age and stage, revealed that in patients with HPV DNA + cancer an absent or low 
fraction of LMP10 nuclear intensity staining was associated to better DFS (p=0.027).This 
was not true for OS. For this group LMP10 nuclear intensity staining, did not show 
statistical significance neither for DFS nor for OS.  
LMP10 staining in the cytoplasm was evaluated again both for the fraction of positive 
cells but also for the intensity of staining and correlated to survival.  A moderate/high as 
compared to low fraction of positively stained cells in the cytoplasm was associated to 
DFS for individuals with HPV DNA- cancer but not for those with HPV DNA+ cancer 
(p=0.003 and p=0.086 respectively). For OS the association was only found to be 
significant for those with HPV DNA- cancer and not for those with HPV DNA+ cancer 
(p=0.001 and p=0.159, respectively). 
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Figure 14: Kaplan-Meier curves by using Log-Rank test, for disease free survival (DFS) and overall survival 
(OS) of patients with TSCC or BOTSCC and stratified according to fraction of cells positive for nuclear 
expression of LMP10. B and E: DFS (B) and OS (E) of patients with HPV-positive TSCC and BOTSCC. C 
and F: DFS (C) and OS (F) of patients with HPV-negative TSCC and BOTSCC. 
LMP10 cytoplasmic intensity staining when compared to absence of staining was 
correlated to a better DFS for patients with HPV DNA- tumors but not for patients with 
HPV DNA+ tumors (p=0.001 and p=0.368, respectively). The same was found for OS and 
the corresponding values were p=0.009 and p=0.334 (Figure 15). 
In a multivariate Cox- regression analysis, separately performed for r HPV DNA+ and 
HPV DNA- groups, including either the fraction of positively stained cells in the 
cytoplasm or the intensity of the cytoplasmic staining and also age and stage of the tumor 
with regard to DFS and OS, revealed that inpatients with HPV DNA- tumors, both a 
moderate/high fraction of positively LMP10 stained cells, and presence of LMP10 
cytoplasmic staining were correlated to better 3-year DFS (p=0.014 and p=0.006, 
respectively) (Table 3). Regarding the corresponding figures for 3-year OS, these were 
p=0.010 and p=0.051 respectively (Table 3). Age and stage at this point, did not reach 
statistical significance in the analysis for patients with HPV DNA- tumors (data not 
shown). The corresponding analysis for the HPV DNA+ group suggested that cytoplasmic 
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LMP10 expression had no association with clinical outcome (3-year DFS and 3-year OS) 
(Table 3). 
 
Figure 15: Kaplan-Meier curves showing disease free survival (DFS) and overall survival (OS) of patients 
with TSCC or BOTSCC, treated stratified according to intensity of cytoplasmic expression of LMP10. B and 
E: DFS (B) and OS (E) of patients with HPV-positive TSCC and BOTSCC. C and F: DFS (C) and OS (F) of 
patients with HPV-negative TSCC and BOTSCC. 
Table 3: Univariable and multivariable analyses on LMP10 staining of TSCC and BOTSCC in relation to 
DFS and OS. 
 
 
  59 
Discussion: In the present study LMP10 was evaluated and scored both for the nuclear 
and cytoplasmic staining including both fraction of positively stained malignant cells and 
intensity of staining in both compartments of the cells. An absent/low fraction of LMP10 
positively stained cells in the nucleus, as well as absent staining intensity in the nucleus, 
was associated to a better DFS for patients with HPV DNA+ cancer, but not for those with 
HPV DNA- cancer. The opposite was observed for cytoplasmic LMP10 staining, where a 
moderate/high fraction of positively stained cells and weak/moderate/high intensity was 
associated to a better DFS and OS in patients with HPV DNA- cancer, but not in those 
with HPV DNA+ cancer.  
The reason for the difference described above is not clear but the separation and evaluation 
of both fraction and intensity of staining has been investigated before for other tumor types 
such as bladder and esophageal cancer but did not show any prognostic significance. 
However, in these studies there was no separation in nuclear and cytoplasmic staining 
which in our case revealed extra information. There are no prior studies on LMP10 
expression in relation to survival in HNSCC and more specifically in OSCC. Meissner et 
al.
201
 demonstrated a correlation with survival in HNSCC for both LMP2 and LMP7, 
which is in accordance with what we found in paper IV. However, the tumors were not 
analyzed for the presence of HPV in any of these studies.  
The difference between the nuclear and cytoplasmic staining with regard to survival 
suggests many implications. It is not known if HPV has the ability to influence the 
expression of LMP10 expression. It has however been shown that E5 has the potential to 
downregulate the expression of HLA class I. If that is the case for LMP10 has to our 
knowledge not been investigated. 
Conclusion: LMP10 expression was in different ways correlated with DFS for both 
patients with HPV DNA+ TSCC and BOTSCC as well as in the HPV DNA- group of 
patients. Thus differential LMP10 expression may have the potential to be used in a 
clinical setting for both groups of patients. 
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4.5 EXPRESSION OF APM COMPONENTS IN RELATION TO HPV STATUS 
AND CLINICAL OUTCOME IN TSCC AND BOTSCC (PAPER IV) 
Aim: To investigate the potential of APM components as prognostic markers in HPV 
positive and negative TSCC and BOTSCC and potentially correlate with HLA class I 
expression especially in HPV positive OSCC.   
Results: The study cohort included 151 tumor samples in total, of which 78 were TSCC and 
73 BOTSCC. In total, 67% of the tumors were HPV DNA+ with 48% being HPV DNA+ for 
TSCC and 52% for BOTSCC. DFS, DSS and OS of patients were analyzed in relation to the 
cytoplasmic and nuclear expression of TAP1, TAP2, LMP2 and LMP7 separately for patients 
with HPV positive and HPV DNA- tumors.  
Nuclear expression of LMP7 was correlated to DFS for both groups, p=0.023 for HPV 
positive and p=0.049 for HPV DNA- tumors. Absence of nuclear staining for LMP7 was 
correlated to increased survival, whereas strong expression correlated with poor prognosis for 
patients with HPV DNA+ tumors, while weak expression was in the intermediate. In 
addition, absence of LMP7 nuclear expression correlated with DSS and OS in patients with 
HPV DNA- tumors (p=0.016 and p=0.042 respectively) (Figure 16).  
LMP2 and its nuclear expression showed a similar trend to that of LMP7 but did not reach 
statistical significance (Figure 15).  
Cytoplasmic LMP2 and LMP7 expression was not associated to survival of the patients. 
Similarly, no significant correlation was found for TAP1 and TAP2 in relation to the clinical 
outcome of the patients. 
Notably, expression was measured and evaluated by intensity of cytoplasmic or nuclear 
staining for TSCC and BOTSCC separately and together and according to HPV status. 
Cytoplasmic expression of LMP10 was reduced in 89% of the tumors, and a similar trend 
was observed for TAP2, LMP2 and LMP7 also reduced in a substantial fraction of tumors 
(33-59%), while TAP1 was only reduced in 9% of the tumors. Similar results were obtained 
for TAP1, TAP2, LMP2, LMP7 and LMP10, nuclear expression with absence in 18-58% of 
the tumors.  
Cytoplasmic and nuclear expression of the different APM components was examined 
separately for TSCC and BOTCC and was in general similar for both. The expression of 
APM components was also evaluated in relation to the HPV status of the tumors. There was 
no difference in TAP1, TAP2, LMP2, and LMP7 expression in HPV DNA+ and HPV DNA- 
tumors, while, as presented in Tertipis et al., in paper IV there was a minor difference with 
regard to cytoplasmic LMP10 expression. 
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Figure 16: Kaplan-Meier curves, by suing Log-Rank test,  for DFS of patients with TSCC and BOTSCC 
stratified by the intensity of staining in the nucleus for LMP2 in HPV-DNA+ (A) and HPV DNA- (B) cases and 
for LMP7 for HPV DNA+ (C) and HPV DNA- (D) cases; n shows the number of patients in each of the groups. 
Expression of the APM components was also correlated to each other to investigate whether 
there was any association between them. This was conducted separately for nuclear and 
cytoplasmic staining. Several significant correlations were found and they are presented in 
Table 4. 
Table 4: Spearman Rank Correlation of cytoplasmic  (left) and nuclear expression (right) of APM 
components 
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Discussion: In this study, absence of LMP7 nuclear expression was correlated to increased 
DFS of patients with HPV positive tumors, with a smiliar trend for LMP2. There was some 
intercorrelations between APM components. For example it has to be mentioned that 
especially the expression of TAP1 and TAP2 molecules were found to be strongly 
correlated and the fact that they are known to be regulated together and are regulated by the 
same promoter, further strengthens our study and implies an indirect proof of the validity of 
the results of our study. There was a general reduction of their expression in the tumors and 
in addition nuclear LMP2 and LMP7 expression was correlated to HLA class I expression 
in HPV DNA+ tumors.  
Reduced expression of the APM components as well as of HLA class I antigens is common  
and has often been shown in many different malignancies and is generally regarded as a 
mechanims of immune evasion. More specifically, it has been shown for HNSCC, laryngeal 
squamous cell carcinoma, cervical and urothelial cancers and also malignant melanoma
198, 
200, 201, 222, 223
. In HNSCC and cervical carcinoma, TAP1, TAP2, LMP2, and LMP7 
expression was frequently reduced, although LMP7 reduction was not as pronounced in the 
latter
200, 201
. The frequencies of absent or reduced TAP1, TAP2, LMP2, and LMP7 
expression in the HNSCC study by Meissner et al. were also somewhat higher than those 
presented here, but in line with our data, TAP1 was less frequently reduced than TAP2.  
APM component expression was evaluated for both cellular compartments since different 
staining patterns were observed. The cytoplasm is assumed to be the active compartment 
for these proteins, but the significance of nuclear staining for peptide presentation by HLA 
class I antigens especially in tumors as well as their effects on the immune response has not 
been investigated thoroughly. Variations in cytoplasmic and nuclear localization of APM 
components have been observed previously. In one report, the thymus presented 
pronounced LMP2 and LMP7 nuclear localization, while in liver cells the distribution of 
LMP2 and LMP7 between the cytoplasm and nucleus was more even
224
.  
Correlations between APM component expression and clinical outcome are generally 
interpreted to be associated to effects on the ability of the immune system to elicit an immune 
response to the tumor. However, LMP2, LMP7, and LMP10 also play a role with regard to 
cell survival and proliferation and protect cells against oxidative damage
225
. A high nuclear 
expression of LMP2 and LMP7 would thus enhance cell survival and proliferation, this way 
resulting in a poorer clinical outcome.  
Conclusion: In HPV DNA+ TSCC and BOTSCC, absent/low nuclear LMP7 expression was 
correlated to better clinical outcome in line with earlier data on absent/low HLA class I 
and/or nuclear LMP10 expression. TAP2, LMP2, and LPM7 expression was, similar to HLA 
class I and LMP10 frequently absent or reduced in many TSCC and BOTSCC, and 
correlations between the analyzed APM components were noted. In addition, for HPV-
positive tumors, LMP2, LMP7 and HLA class I expression were correlated.  
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4.6 A MODEL FOR PREDICTING CLINICAL OUTCOME OF PATIENTS WITH 
HPV POSITIVE TSCC AND BOTSCC (PAPER VI) 
Aim: To combine our so far best predictive molecular markers and clinical characteristics of 
the patients into a single algorithm for predicting the clinical outcome of individual patients 
with HPV DNA+ and p16+ TSCC and BOTSCC. 
Results: The study was initiated on a training cohort of 197 patients diagnosed during 2000–
2007, and validated on a cohort of 118 patients from 2008–2011. A regularized logistic 
regression was used and coefficients were generated for each of the parameters included in 
the model. The model provided specific coefficients for the different markers and in this way, 
also individual patient risk scores and predicted probabilities for 3 year D/R (Death or relapse 
of the patient). Individual risk scores for each patient are obtained after the multiplication of 
the coefficient for each variable multiplied by the value of each patient for the corresponding 
predictor and finally by summing all the products from all the predictors (Table 5). 
Table 5: Predictor variables and summary scores for the regularized logistic regression model of patients 
included in the training cohort. 
Variable Coefficient Patient 1 Patient 2 Patient 3 
Age at diagnosis 3.727 61 51 60 
CD8+TILsa −18.848 1.10 4.69 1.31 
Stage 51.086 2 1 2 
HLA class I (HC10-intensity) 27.429 2 0 1 
BOTSCC −2.653 0 1 0 
CD8+ TILsa Stage −10.773    
Risk score  339.9 99.6 300.3 
Probability of eventb  0.40 0.06 0.31 
aCD8+ TIL counts are measured as loge count +1.   
bEvent is defined as 3-year D/R.    
 
High scores after the aforementioned multiplications correspond to high risk while low scores 
correspond to low risks. For that as it is presented in Table 5 above, a low risk for 3-year D/R 
is associated with younger age, lower stage, absent HLA class I as it is given by HC10 
intensity and high CD8+ TIL counts, while minor contributions were offered by BOTSCC 
diagnosis. Also, in the model there was an interaction term as it is called and this is the 
CD8*Stage term which shows the fact that the total effect of the CD8+ TILs is dependent on 
the patients’ tumor stage. The discriminative power of the model gave an AUC of 0.77 which 
is acceptable and was not diminished after calibration of the model.  
The risk score (x) for a specific patient is given by multiplying all the different scores for 
each individual component of the model as presented in Table 5. Thus,  
x= 3.727*(age) – 18.848*(CD8+TILs) + 51.086*(stage) + 27.429*(HC10 intensity) – 
2.653*(Diagnosis) – 10.773*(CD8+TILs*Stage). 
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The probability (p) of an event is then calculated by the equation below: 
𝒑 =
𝟏
𝟏 + 𝐞𝐱𝐩⁡(−(−𝟑. 𝟕𝟖𝟕 +
𝒙
𝟏𝟎𝟎))
 
 
As mentioned previously, the model was generated based on an initial cohort of 197 patients 
and was validated on an additional cohort of 118 patients. Both of the cohorts were very 
similar with the only exception being that the proportion of patients treated with conventional 
treatment was lower in the validation cohort reflecting the recent change in the trends for 
treatment of HNSCC. In the validation of the model the discriminative power remained 
almost the same (AUC=0.77, 95% CI). High CD8+ TIL counts retained a positive influence, 
but the significance of HLA class I expression was no longer prominent.  
Discussion: In this study, a prediction model was generated for 3-year D/R based on clinical 
and biomarker data from patients with HPV DNA+ and p16+ TSCC and BOTSCC. The 
predictor variables included in the model were age, stage, diagnosis HLA class I expression, 
and CD8+ TIL counts. The predictive model effectively separated patients who died or 
relapsed within 3-years from those who had a 3-year progression-free survival. It also 
allowed for predicting risk of an event for individual patients. The model showed that a low 
risk is associated with younger age, lower stage, absent HLA class I as it is given by HC10 
intensity and high CD8+ TIL counts. All the aforementioned variables have been previously 
shown to have an impact on favorable clinical outcome. It can be clearly seen that from the 
molecular markers included in the model that CD8+ TILs and HLA are both associated with 
immunity and we hypothesize that the downregulated HLA class I is due to HPV and upon 
treatment expression is restored allowing for immune recognition and elimination.  
The model has its benefits and limitations. One difficulty in the development of the model is 
that the overall survival of patients with HPV positive tumors is very high and the numbers of 
events, i.e. death, or recurrence, are very few. This limits the numbers of biomarkers and 
clinical markers that can be included into the model when using a restricted number of 
patients.  
There were also some revelations during this exercise in that CD44 and smoking, two 
biomarkers previously suggested to be of prognostic importance did not add to the predictive 
value of the model. For smoking it may be due to that the information given in the case 
reports is incomplete. However, it is also possible that some of the findings revealed here are 
because we only examine data for patients with HPV DNA+ p16+ tumors, and in these 
patients survival is generally slightly better than for those with only HPV DNA+ tumors. 
It is well known in our field of head neck cancer and especially OSCC that smoking is a risk 
factor. The impact of smoking including package years has been studied extensively for 
patients with HPV DNA+ or p16+ tumors separately, but not specifically for those positive 
for both HPV DNA/p16
56, 226
.  
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In our case, smoking was not included in the model due to the fact that it is a variable that is 
not well documented in our cohorts and it is not possible to calculate number of pack years.  
The fact that treatment was not included in the model may suggest that the prognosis for a 
patient with HPV DNA+/p16+ TSCC or BOTSCC given conventional treatment might not 
differ much from the prognosis for the same patient with intensified treatment. The latter is 
supported by a study from Attner et al., 2012
227
 but it still remains to be elucidated and 
additional data and studies are in need to explore if this is indeed the case.  
Conclusion: The present study demonstrates that combined information from several 
markers and clinical variables can be used in order to predict outcome with high accuracy, 
also on the individual patient level. Secondly, patient-specific probabilities of 3-year D/R 
were produced and the data could be validated on a new cohort. The generated model can be 
further refined with additional biomarkers and can also be evaluated in larger patient groups.  
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5 CONCLUSIONS 
 
 Patients with HPV DNA+ (including those with HPV DNA+/p16+) and TSCC and 
BOTSCC have in general higher numbers of CD8+ TILs than those with HPV DNA- 
TSCC and BOTSCC.   
 
 High numbers of CD8+ TILs are associated with a better clinical outcome in TSCC 
and BOTSCC patients in general and especially in patients with HPV DNA+ 
(including those with HPV DNA+/p16+) tumors (Paper I). 
 
 Patients with HPV DNA+ OSCC with absent/low expression of HLA class I intensity 
staining present a very high DFS, DSS and OS (independent of the treatment regime) 
as compared to DFS, DSS and OS of  patients with HPV DNA+ OSCC with strong 
HLA class I intensity (Paper II). 
 
 Patients with HPV DNA- OSCC with a strong HLA class I intensity and/or HLA 
class II intensity present a better clinical outcome that those with HPV DNA- tumors 
and absence of HLA class I and/ or HLA class II (Paper II). 
 
 The presence of the HLA-A*02 allele which is common in the Scandinavian 
population is not increased in OSCC, but is a negative prognostic factor for patients 
with HPV DNA+ OSCC and absence of it is correlated with increased DFS of 
patients with HPV DNA+ tumors (Paper III). 
 
 Components of the antigen processiong machinery (APM) such as LMP7 and LMP10 
and their expression are associated with increased survival of patients with HPV 
DNA+ TSCC and BOTSCC. More specifically, absence of LMP7 and LMP10 
nuclear staining is correlated with increased DFS of patients with HPV DNA+ tumors 
(Papers IV and V). 
 
 Cytoplasmic expression of LMP10 is associated with increased survival of patients 
with HPV DNA- TSCC and BOTSCC (Paper IV). 
 
 Expression of APM components is often downregulated in TSCC and BOTSCC. 
Their expression is often intercorrelated. (Paper V). 
 
 A model comprising information from clinical and molecular marker characteristics 
of the patients was able to predict the individual patient clinical outcome and produce 
specific probablities for 3-year D/R for the patients. Predictors included in the model 
were age, tumor stage, CD8 TIL counts and HC10 intensity staining (Paper VI).  
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6 FUTURE PERSPECTIVES AND GOALS 
In this thesis, the potential of different immunological molecules implicated in antigen 
presentation and immune recognition, to serve as prognostic biomarkers for clinical outcome 
of patients with HPV positive and negative OSCC and more specifically TSCC and BOTSCC 
were examined. 
A handful of biomarkers associated with the antigen processing machinery and antigen 
presentation were identified as good prognostic biomarkers. Some of these e.g. CD8+ TILs 
and the HLA class I molecules, have been studied in many different malignancies showing 
prognostic significance. 
The specificity and sensitivity of each biomarker differed, and some biomarkers identified 
patients with good clinical outcome with high accuracy, but selected few patients. Other 
markers were less specific and selected out a larger number of patients. Therefore we needed 
to combine and investigate the potential of building up a prediction model, which utilized and 
combined several molecular biomarkers and clinical characteristics in a way that serves as a 
prediction tool. This was performed in paper IV, resulting in the individual prediction and 
probabilities of events with high accuracy. 
To strengthen our model even further, more biomarkers and larger patient cohorts would be 
useful, to develop an even more robust model to identify patients with good prognosis and 
select out patients that respond to less intensive treatment. The latter is of specific importance 
in the future to be able to conduct randomized trials with de-escalated treatment.   
The main focus of future studies would in my opinion be to identify additional biomarkers 
that could strengthen our model and also an inclusion of more detailed information on 
smoking and snuff would be of importance. Furthermore, more extensive studies should be 
conducted on the basis of combining several markers, and at the same time randomizing into 
conventional and accelerated treatment. 
Additional biomarkers could be investigated on the RNA and DNA level and combined with 
the current ones. Although IHC is routine in clinical pathology, other technologies are already 
on their way allowing for the application of more advanced techniques in the pathology units, 
e.g. genome or transcriptome sequencing, has the potential to in short time (assay time) 
generate prognostic information. 
Last but not least, mechanisms of HLA downregulation should be elucidated and explored on 
the molecular level to disclose a possible influence of HPV in this respect on several of the 
molecular markers investigated here. 
Questions will always require an answer, but that is how science goes forward… New 
answers bring new question and so on… Keep on asking yourself … 
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